

# Solvency and Financial Condition Report (SFCR) 2020

Canada Life International Assurance (Ireland) DAC

# Contents

Reference Tables .....	4
Reference Figures .....	4
List of Abbreviations and Acronyms .....	5
Executive Summary .....	6
<b>A. Business and Performance .....</b>	<b>9</b>
A.1 Business and External Environment .....	9
A.2 Performance from Underwriting Activities .....	12
A.3 Investment Performance .....	13
A.4 Performance of Other Activities .....	15
<b>B. Systems of Governance .....</b>	<b>16</b>
B.1 General Information on the System of Governance .....	16
B.1.1 Risk Governance Structure .....	16
B.1.2 Key Function Holders .....	19
B.1.3 Adequacy of Review and Systems of Governance .....	20
B.1.4 Remuneration Practices .....	20
B.1.5 Control Functions .....	22
B.2 Fit and Proper Requirements .....	22
B.3 Risk Management System Including the	
‘Own Risk and Solvency Assessment’ .....	23
B.3.1 Risk Management Framework –	
Three Lines of Defence .....	24
B.3.2 Enterprise Risk Management (ERM) Framework .....	25
B.3.3 Risk Appetite .....	25
B.3.4 Risk Identification, Assessment and Treatment .....	26
B.3.5 Risk Measurement .....	26
B.3.6 ORSA .....	27

B.4 Internal Control System .....	28
B.4.1 Internal Control System .....	28
B.4.2 Compliance Function .....	29
B.5 Internal Audit Function .....	29
B.6 Actuarial Function .....	30
B.7 Outsourcing .....	31
B.8 Any Other Information .....	32
<b>C. Risk Profile .....</b>	<b>33</b>
C.1 Underwriting Risk .....	34
C.1.1 Investment Assets and Prudent Person Principle as applied to Underwriting Risks .....	34
C.1.2 Underwriting Risk Concentration .....	34
C.1.3 Assessment and Risk Mitigation Techniques used for Underwriting Risks .....	34
C.1.4 Risk Sensitivity for Underwriting Risk .....	35
C.2 Market Risk .....	35
C.2.1 Investment Assets and Prudent Person Principle as applied to Market Risks .....	35
C.2.2 Market Risk Concentration .....	36
C.2.3 Assessment and Risk Mitigation Techniques used for Market Risks .....	36
C.2.4 Risk Sensitivity for Market Risks .....	36
C.3 Credit Risk .....	36
C.3.1 Investment Assets and Prudent Person Principle as applied to Credit Risks .....	37
C.3.2 Credit Risk Concentration .....	37
C.3.3 Assessment and Risk Mitigation Techniques used for Credit Risk .....	37

# Contents

C.4 Liquidity Risk.....	37	E. Capital Management.....	45
C.4.1 Investment Assets and Prudent Person Principle as applied to Liquidity Risks.....	37	E.1 Own Funds.....	45
C.4.2 Liquidity Risk Concentration .....	37	E.2 Solvency Capital Requirement and Minimum Capital Requirement .....	47
C.4.3 Assessment and Risk Mitigation Techniques used for Liquidity Risk.....	38	E.3 Use of the Duration-based Equity Risk Sub-Module in the Calculation of the Solvency Capital Requirement.....	48
C.4.4 Risk Sensitivity for Liquidity Risk .....	38	E.4 Differences between the Standard Formula and any Internal Model Used .....	48
C.4.5 Additional Information for Liquidity Risk .....	38	E.5 Non-compliance with the Minimum Capital Requirement and Non-Compliance with the Solvency Capital Requirement.....	48
C.5 Operational Risk.....	38	E.6 Any Other Information .....	48
C.5.1 Investment Assets and Prudent Person Principle as applied to Operational Risks.....	39	F. Appendix .....	49
C.5.2 Operational Risk Concentration .....	39		
C.5.3 Assessment and Risk Mitigation Techniques used for Operational Risk .....	39		
C.5.4 Risk Sensitivity for Operational Risk .....	39		
C.6 Other Material Risks.....	39		
C.7 Any Other Information .....	40		
D. Valuation for Solvency Purposes .....	41		
D.1 Assets .....	41		
D.1.1 Overview of Methodology for Valuing Assets .....	41		
D.2 Technical Provisions .....	42		
D.3 Other Liabilities.....	44		
D.4 Alternative Methods for Valuation.....	44		
D.5 Any Other Information .....	44		

## Reference Tables

Table 1:	Abbreviations and Acronyms.....	5
Table 2:	Underwriting Income and Expenses.....	12
Table 3:	Underwriting Performance 2020 .....	12
Table 4:	Underwriting Performance 2019 .....	12
Table 5:	Investment Income.....	13
Table 6:	Fair Value Adjustment.....	14
Table 7:	Shareholder Investment Income 2020 .....	14
Table 8:	Shareholder Investment Income 2019 .....	14
Table 9:	Asset by Class .....	15
Table 10:	CLIAI Remuneration Programmes .....	21
Table 11:	Three Lines of Defence .....	24
Table 12:	Service Providers.....	32
Table 13:	Material Solvency II assets (Extract from Appendix) .....	41
Table 14:	Technical Provisions (extract from Appendix).....	42
Table 15:	Assumptions .....	43
Table 16:	Other Liabilities (extract from Appendix) .....	44
Table 17:	Basic Own Funds (extract from Appendix) .....	45
Table 18:	Reconciliation Reserve.....	46
Table 19:	Available and eligible own funds (extract from Appendix).....	46
Table 20:	Solvency Capital Requirement and Minimum Capital Requirement.....	47
Table 21:	Movement in SCR and MCR year end 2019 and year end 2020 .....	48

## Reference Figures

Figure 1:	Simplified GWL organisational structure .....	9
Figure 2:	Standard Formula Structure.....	33
Figure 3:	Basic SCR Components.....	33

## List of Abbreviations and Acronyms

BAC	Board Audit Committee
BEL	Best Estimate Liability
BRC	Board Risk Committee
BSCR	Basic Solvency Capital Requirement
CAL	Capacity, Appetites and Limits
CBI	Central Bank of Ireland
CCO	Company Compliance Officer
CEO	Chief Executive Officer
CFO	Chief Financial Officer
CIA	Chief Internal Auditor
CLG	The Canada Life Group (UK) Limited
CLIAI	Canada Life International Assurance (Ireland) DAC
CLIHC	Canada Life Irish Holding Company Ltd
CLIS	Canada Life Investment Services Limited
CLL	Canada Life Limited
CRB	Capital Redemption Bond
CRO	Chief Risk Officer
DFM	Discretionary Fund Manager
EIOPA	European Insurance and Occupational Pensions Authority
EMC	Executive Management Committee
ERM	Enterprise Risk Management
EU-IFRS	International Financial Reporting Standards

EUR	Euro
FCA	Financial Conduct Authority
FIP	Flexible Investment Portfolio
F&P	Fitness and Probity
GBP	Great British Pound (Sterling)
GWL	Great-West Life
GWLG	Great West Life Group
HoF	Head of Finance
HoAF	Head of Actuarial Function
IPB	International Portfolio Bond
IS	Information Systems
MLRO	Money Laundering Reporting Officer
ORSA	Own Risk and Solvency Assessment
OSFI	Office of the Superintendent of Financial Institutions
PEA	Premiere Europe Account
PRA	Prudential Regulation Authority
SCR	Solvency Capital Requirement
SPV	Special Purpose Vehicle
TPA	Third Party Agreement
VAT	Value Added Tax
WPEA	Wealth Preservation Europe Account

Table 1: Abbreviations and Acronyms

# Executive Summary

The Solvency II Directive published in 2009, and formal clarifications published since then, requires narrative and quantitative disclosures from all regulated European insurance entities.

In accordance with the Solvency II Directive, the Solvency and Financial Condition Report (SFCR) is required to be published annually by Canada Life International Assurance (Ireland) DAC (CLIAI). The purpose of the SFCR is to provide policyholders with a concise overview of the business written, system of governance, risk profile and solvency position over the reported year.

This report has been drafted for the purpose of public disclosure, in line with requirements and structure defined by the European Insurance and Occupational Pensions Authority (EIOPA). The report provides an overview of CLIAI's business, describes how the Company is run and governed, outlines methodologies and assumptions used in the valuation of assets, liabilities and capital requirements, and highlights, where appropriate, material expert judgements that have been applied while also indicating any areas of uncertainty. Any material differences between the Solvency II regulatory reporting basis and the financial statements of CLIAI are provided.

Where possible, this report has been prepared on the basis of existing policies and other relevant documents as reviewed and approved within the governance structures in CLIAI. The report has been written as a standalone document so that reference to other documents is not required to understand the content.

Unless otherwise specified, this report is based on results and methodology pertaining to CLIAI as at 31st December 2020. Each section of the report is summarised below.

## A. Business Overview

Canada Life International Assurance (Ireland) DAC (CLIAI) was originally established in Ireland under the name Legal & General International (Ireland) Limited in May 2007. In July 2015 the Company was acquired by The Canada Life Group (U.K.) Limited (CLG).

CLIAI is based in Dublin which is recognised as one of the world's leading financial centres. The company boasts a strong commitment to international financial standards and policyholder protection. Our aim is to provide a range of long term wealth management solutions principally to the UK market. CLIAI and a sister company, Canada Life International Limited, based in the Isle of Man represent the International Division of Canada Life UK offering policyholders and advisers jurisdictional choice.

CLIAI provides the tax efficiency of investing through a Dublin-based company, where the underlying investment can grow free of UK tax, with any personal taxation usually being deferred until profits are brought back to the UK market.

CLIAI offers a number of products to its customers. These include the International Portfolio Bond (IPB) (closed to new business in March 2018), the Premiere Europe Account (PEA) {including a Capital Redemption Bond (CRB) option} and the Wealth Preservation Europe Account (WPEA). All products offer a wide range of investment options including investment in mutual funds and deposits.

CLIAI also operates in Italy on a freedom of services basis. CLIAI closed to new business in the Italian market in May 2015. Additional 'top-up' investments to the Flexible Investment Portfolio (FIP) product continued to be accepted from existing policyholders until the 8th March 2019.

# Executive Summary

The administration of these products is largely outsourced to Canada Life International Services Limited (CLIS) with the exception of the FIP which continues to be administered in CLIAI.

New business activity for 2020 was £468m compared to £882m in 2019, 47% lower than the prior year. The uncertainty caused by COVID-19 has led to a general economic downward trend impacting new business performance.

CLIAI has been engaged in extensive Brexit planning since the UK voted to leave the European Union (EU). The UK and the EU negotiated a withdrawal agreement, including a transition period, in October 2019 which was subsequently approved by both the UK Parliament and the European Parliament. As both Parliaments voted in favour of the withdrawal agreement, the UK left the EU at 11pm on 31st January 2020 and entered a Transition Period which lasted until 31st December 2020. During this period, all EU rules and regulations continued to apply to the UK.

CLIAI developed a post-Brexit operating model supported by external legal counsel and engaged with all appropriate Regulators in Ireland and the UK during the process.

CLIAI ensured that advisers and policyholders were kept informed of the relevant Brexit issues throughout 2020 and how these may impact their policies. Further communications are planned for early 2021.

With the backdrop of COVID-19 the directors have confirmed their assessment that the company continues to operate as a going concern. The directors review quarterly financial performance, liquidity measures and the performance of our shareholder assets. Whilst the lower sales of investment bonds in the period will have a short term impact on fee income, the company is in a strong cash position and can sustain lower fee revenue for a significant timeframe and not deviate materially from the company's business plans.

## B. Systems of Governance

The Board of Directors of CLIAI are responsible for the governance and oversight of risks to which CLIAI is exposed. The Board has assigned key duties and responsibilities in relation to risk identification, assessment, measurement, monitoring and control to the Board Risk Committee (BRC). The Company has a comprehensive Risk Management Framework in place for this purpose. The BRC is responsible for providing advice to the Board in its oversight of the Company's principal risks.

## C. Risk Profile

CLIAI's objective in the management of risk is to minimise, where practicable, its exposure to risk, except when necessary to support other business objectives.

CLIAI's main quantitative measurement of risks is via application of the standard formula set out by the Solvency II Directive and Delegated Regulations. The Solvency II standard formula Solvency Capital Requirement (SCR) sets out how much capital a company must hold against the risks on its balance sheet.

An analysis of the Company's risk profile, including risk sensitivity, concentration and risk mitigation techniques is provided in Section C.

# Executive Summary

## D. Valuation

The main focus of Solvency II reporting is the measurement of financial strength (capital resources) of the insurer, as opposed to its performance during the year. As such, the Solvency II balance sheet is intended to reflect an economic valuation of all assets and liabilities of the business at the balance sheet date.

An analysis of the valuation of the Company's assets and liabilities per the Solvency II balance sheet (in Appendix) is provided in the report in Sections D.1 Assets and D.3 Other Liabilities. Technical provisions are discussed in Section D.2.

## E. Capital Management

The aim of CLIAI's capital management strategy is to ensure the company has sufficient capital, reserves and liquidity to meet its liabilities as they fall due and to meet regulatory solvency requirements. The ratio of CLIAI's available capital to its regulatory SCR was 150.78% of SCR as at 31st December 2020, compared to 164.5% as at 31st December 2019, indicating capital resources were well in excess of both the regulatory minimum and the Board's targeted minimum level of 130%. Table 21 sets out the drivers of the movements in the SCR over the year.



## A. Business and Performance

### A.1 Business and External Environment

Canada Life International Assurance (Ireland) DAC (CLIAI) was established in Ireland under the name Legal & General International (Ireland) Ltd in May 2007. In July 2015 the Company was acquired by The Canada Life Group (U.K.) Limited (CLG). At 31st December 2018 the ordinary share capital in the Company was 80% held by CLG, with the remaining 20% held by CL Abbey Limited (100% owned by CLG). The latter shareholding results from the High Court approved portfolio transfer of CL Abbey (formerly named Canada Life International Assurance Limited) to CLIAI which took place on 1st January 2016, and had no impact on ultimate control of the Company. Voting rights are aligned to the ordinary shareholding proportions.

In March 2019, in preparation for Brexit, the group restructured its businesses and CLG transferred its shareholdings in CLIAI and CL Abbey Life to CLIHC, following approval by the Central Bank of Ireland. The purpose of this restructure was to move all Irish Solvency II reporting entities under an EU based holding company as The Canada Life Group (UK) Limited is registered in the UK and is located outside the EU post Brexit.

The Company is part of Great-West Lifeco Inc. Great-West Lifeco Inc. and its subsidiaries, including The Great-West Life Assurance Company, have approximately \$1.98 trillion Canadian dollars in consolidated assets under administration and are members of the Power Corporation Group of companies.

From a business perspective, CLIAI is part of the Wealth Management Division of Canada Life UK with Canada Life International Limited (CLI), which is based in the Isle of Man. The strategy of the International Division is to offer a wide range of investment and insurance products principally to the UK market. Combined assets under administration of both businesses are almost £19bn. CLIAI has a 5 Star AKG rating, as does CLI, meaning all of our International operations share this accolade.




Figure 1: Simplified GWL organisational structure as at 31st December 2020

The Company operates as a life assurance company authorised to sell assurance policies linked to investment funds and capital redemption products. CLIAI is focused on long term investment and wealth protection business for high net worth clients. The Company works together with our outsourced policy administration provider, Canada Life Investment Services Limited, to ensure investment requirements of customers are met with optimised service delivery.

CLIAI is authorised and regulated by the Central Bank of Ireland (CBI), New Wapping Street, North Wall Quay, Dublin 1 since July 2007. It forms part of CLG which is subject to Group Supervision led by the Prudential Regulation Authority (PRA), 20 Moorgate, London, EC2R 6DA. From the 1st January 2021, CLIHC will be subject to Group Supervision, in relation to CLIAI, led by the Central Bank of Ireland.

CLIAI is a Category A Insurance Permit holder issued by the Jersey Financial Services Commission, PO Box 267, 14-18 Castle Street, St Helier, Jersey, JE4 8TP, Channel Islands.

The Company has its registered office at the Irish Life Centre, Lower Abbey Street, Dublin 1 in Ireland. The Company's external auditors are Deloitte Ireland LLP, Deloitte & Touche House, Earlsfort Terrace, Dublin 2.

## A. Business and Performance

### Material Lines of Business and Geographical Areas

CLIAI offers unit-linked life assurance bonds to UK residents through UK independent regulated intermediary channels. The main market for CLIAI is the UK. The company also holds a 'Category A' insurance permit with the Jersey Financial Services Commission to sell to Jersey residents through similar independent sales channels. CLIAI closed to new business in the Italian market in May 2015. CLIAI stopped accepting additional 'top-up' investments to the Flexible Investment Portfolio (FIP) on 8th March 2019. The company is now closed to all business from the Italian market.

CLIAI offers a number of products including: the Premiere Europe Account (PEA) {including a Capital Redemption Bond (CRB) option} and the Wealth Preservation Europe Account (WPEA). The International Portfolio Bond (IPB) was closed to new business in March 2018. All products offer a wide range of investment options including investment in mutual funds and deposits.

All products are developed to assist high net worth clients with their investment management and tax planning needs. In all cases apart from the CRB option, the investment risk is taken by the policyholder. For the CRB option, some investment risk is taken by the company since a small investment guarantee is provided if the policies are held for 99 years. All products offer a wide range of investment options including investment in mutual funds and deposits.

The key benefits of CLIAI's products to UK policyholders include the following:

- The tax efficient growth of an investment based in Ireland for UK residents means that any growth is not subject to UK tax, although UK tax may apply when any profit made is brought back into the UK.
- It is set up as a series of identical policies, providing flexibility when a policyholder wants to withdraw money from the investment.
- It can be denominated in Sterling, US dollars or Euro – this can be an advantage if a policyholder is planning to move abroad and wants to reduce the effect of changes in exchange rates.
- Beneficial VAT status of any fees payable to Discretionary Fund Managers (DFM's).

- A policyholder or their adviser can change the underlying investments of the bond at any time without a tax charge.
- Flexibility, as individual policies can be gifted to new owners without a tax charge.
- For trustees it can offer an easy method of investing.

The funds in which policyholder premiums are invested are selected by the policyholders themselves, and reflect each individual's personal risk preferences. CLIAI's policyholder funds can be broadly split into two categories, as follows:

- Direct Holdings; whereby a policyholder directly selects the assets that they want to invest in, and CLIAI uses the policyholder's premium to purchase the assets on the policyholder's behalf; and
- DFM's and Platforms; where a DFM is nominated by the policyholder, they invest the funds in a variety of asset classes in line with the policyholder's investment attitude to risk. Where the policyholder nominates an external investment platform, an independent investment adviser invests the funds on the policyholders' behalf. CLIAI has a legal agreement in place with each of the DFM's and Platform Providers.

### Significant Business or External Events over the Reporting Period

#### *Brexit*

Since the UK voted to leave the European Union (EU), the two sides have been negotiating the terms of the UK's withdrawal and its future relationship with the EU.

The UK and the EU negotiated a withdrawal agreement, including a transition period, in October 2019 which was subsequently approved by both the UK Parliament and the European Parliament. As both Parliaments voted in favour of the withdrawal agreement, the UK left the EU at 11pm on 31 January 2020 and entered a transition period which lasted until 31 December 2020. During this period, all EU rules and regulations continued to apply to the UK.

## A. Business and Performance

Throughout 2020, we continued to monitor the situation closely and work with all stakeholders (including professional advisers, discretionary fund managers, external legal and tax advisers and all appropriate regulators) to plan for a smooth transition. Our focus was to continue to meet our contractual, regulatory and legal obligations and on ensuring good customer outcomes regardless of the terms of withdrawal. Following the end of the transition period it is clear that CLIAI will continue to be subject to the same EU regulatory regime as currently applies. CLIAI has confirmed to all stakeholders that new and existing policies will remain valid and enforceable after the end of this period.

We have ensured that our international business can continue to offer the choice of Isle of Man and Ireland jurisdictions to advisers and clients, and are able to continue service our customers. One aspect we expected to change related to the Financial Services Compensation Scheme (FSCS). The FSCS provided protection for UK-resident policyholders of EU-authorised life assurance companies such as CLIAI. This is no longer the case and the position has been communicated to all stakeholders.

Although there is no formal insurance policyholder protection compensation scheme in Ireland there are a number of regulatory measures in place to protect all policyholders of a company such as CLIAI in the event that the company is unable to meet its financial commitments.

CLIAI is an Irish-regulated life assurance company and, as such, it is required to segregate policyholder assets from those of shareholders. In this way the shareholder cannot use the policyholder's assets to support its financial position. There are also restrictions on the types of assets the life company can hold to meet its policyholder liabilities. The purpose of these restrictions is to limit exposure to riskier or more volatile assets. The company's Head of Actuarial Function (HoAF) reports to the Central Bank of Ireland (CBI) in this regard on an annual basis and the HoAF is also required to ensure that at all times the policyholder's interests are represented in the company's decision making process.

European Union legislation sets out requirements of EU-authorised life assurance companies to hold a solvency capital requirement (SCR) calculated using a risk-based approach. Like other life companies, CLIAI must hold additional assets at least equal to the value of the SCR.

The CBI has various powers of intervention if they become concerned about the solvency of a life assurance company. CLIAI is required to make annual solvency submissions to the CBI, and is subject to regular internal and external audit activity and inspection by the CBI. This means that CLIAI is regularly reviewed by the CBI to ensure it meets the legal and regulatory requirements in Ireland.

Irish law and regulation that governs the winding-up of life companies in Ireland means that policyholder liabilities must be paid ahead of any other claims of the life assurance company other than the cost of winding up the company.

As part of our ongoing Brexit preparedness planning management made a commitment to communicate with all stakeholders once there was a degree of certainty in the Brexit process. CLIAI implemented a communication plan in early February 2020 to communicate with all stakeholders including policyholders and regulated intermediaries.

A follow-up communication for all stakeholders is planned for January 2021 after the end of the transition period.

Engagement on Brexit contingency planning continued with the CBI throughout 2020 including the sharing of preparedness and contingency plans developed by the business.

## A. Business and Performance

### A.2 Performance from Underwriting Activities

As the Company operates one line of business, unit-linked bonds distributed to the UK market and a closed book of Italian business, all performance analysis is based on this business line.

Investment contract liabilities – as per Financial Statements	As at 31st Dec 2020 £m	As at 31st Dec 2019 £m
Opening Investment Contract Liabilities	6,112.51	4,798.50
Premiums	468.41	881.93
Claims	-231.29	-218.98
Investment return credited net of related charges	384.65	675.70
Management charges and other fee deductions	-10.30	-12.37
Other movements (includes opening valuation of transferred former Canada Life International Assurance book)	-8.47	-12.28
<b>Closing Investment Contract Liabilities</b>	<b>6,715.50</b>	<b>6,112.51</b>

Table 2: Underwriting Income and Expenses

New business activity for 2020 was £468m compared to £882m in 2019, 47% lower than the prior year. The uncertainty caused by COVID-19 has led to a general economic downward trend impacting new business performance.

Premiums, claims and expenses by country	UK £m	Italy £m	TOTAL 2020 £m
Premiums	468.41	0.00	468.41
Claims	-221.54	-9.74	-231.28
Change in other technical provisions	365.19	0.68	365.87
Expenses	-12.94	-0.53	-13.47
<b>Underwriting Performance</b>	<b>599.12</b>	<b>-9.59</b>	<b>589.53</b>

Table 3: Underwriting Performance 2020

Claims have increased by 6% in the year. An increase in claims is in line with the Company's expectations due to the decision to close the Italian book to top ups in 2018 and due to the maturity of the UK book and growth in Assets Under Management in 2020.

Change in other technical provision of £365m reflects unrealised gains on the policyholders' investment portfolio, primarily due to market gains in H2 2020.

Premiums, claims and expenses by country	UK £m	Italy £m	TOTAL 2019 £m
Premiums	881.93	0.04	881.97
Claims	-202.70	-16.28	-218.98
Change in other technical provisions	651.996	-0.94	651.06
Expenses	-12.78	-1.03	-13.81
<b>Underwriting Performance</b>	<b>1,318.45</b>	<b>-18.21</b>	<b>1,300.24</b>

Table 4: Underwriting Performance 2019

## A. Business and Performance

### A.3 Investment Performance

Investment of shareholders' funds is governed mainly by liquidity and solvency considerations, including compliance with the regulations and guidelines specified by the regulator. Expected returns, dividend policy and operational constraints are also factors considered when setting the investment policy of shareholders' funds.

The Company aims to back the technical provisions and solvency capital requirement with secure assets, primarily short to medium term sovereign bonds and cash deposits.

The Company's annual financial statements are reported in GBP. With the costs of the Company's head office largely denominated in EUR this causes some exposure to fluctuations in the GBP/EUR foreign exchange rate.

The shareholder investment policy is geared towards holding an appropriate mix of assets in EUR and GBP which will have the effect of managing exposure to currency movements. Notwithstanding this, foreign exchange fluctuations in the period have led to gains on our EUR denominated shareholder investments. This is due to the movement of the EUR to GBP exchange rate over the reporting period. Foreign exchange gains total £1.2m on shareholder assets at December 2020, as opposed to a £1.5m loss for the prior year.

Investment & Expenses	Financial Year ended 31st Dec 2020 (£m)	Financial Year ended 31st Dec 2019 (£m)
<b>Financial assets other than those at fair value through profit and loss:</b>		
Interest income – cash and cash equivalents	0.22	0.37
Interest, dividends and other	84.26	62.98
Equity securities and interests in pooled investment funds	0.63	0.67
Debt securities	-0.08	-0.07
<b>Investment Income Total</b>	<b>85.03</b>	<b>63.95</b>
Investment expenses and charge	-0.06	-0.25

Table 5: Investment Income

Interest income from cash and cash equivalents has decreased year on year mainly due to lower deposit interest rates available in the market. Interest, dividends and other income increased by 34%. This is primarily due to increased realised gains on policyholder investments. Income from equity securities and interests in pooled investment funds is down 6% on 2019, due to lower rebate income in the year.

Investment income from interest on debt securities is a negative £0.08m, due primarily to realised losses on the sale of bonds.

## A. Business and Performance

Fair value adjustments	Financial Year ended 31st Dec 2020 (£m)	Financial Year ended 31st Dec 2019 (£m)
<b>Net unrealised gains/losses</b>		
Equity securities and interests in pooled investment funds	299.83	612.51
Debt securities	0.05	0.02
	<b>299.88</b>	<b>612.53</b>

Table 6: Fair Value Adjustment

Net unrealised gains/losses on equity securities and interests in pooled investment funds have seen a decrease due to adverse market valuation movements on policyholder funds. This movement has no impact on profitability as it is offset entirely by movements in the Company's associated unit reserves but does reflect a positive performance in the underlying investments for the policyholder in the year.

Fair value adjustments through the income statement on debt securities reflect total gains of £0.05m (2019: £0.02m gains).

### Shareholder Income, Gains/Losses by asset class

Net investment income from shareholder assets was £0.49m in 2020 compared with £0.74m in 2019. Income from the portfolio of Government bonds resulted in interest received of £0.25m and Corporate bonds produced £0.04m of interest. This was due to a broad reduction in coupons due to the available yields on the portfolio held. Cash and deposits portfolio produced £0.20m of interest in 2020, the decrease is due to lower deposit rates available for medium term GBP deposits in the market. Fair value movements resulted in a small unrealised gain of £0.06m in the bond & equity portfolio compared with gains of £0.2m in 2019.

No investments in securitisations are held on the balance sheet.

2020 Asset Class	Interest (£m)	Net Gains and Losses (£m)	Unrealised gains and losses (£m)
Government Bonds	0.25	-0.38	0.02
Corporate Bonds	0.04	0.00	0.03
Equity	-	-0.01	0.01
Cash and Deposits	0.20	-	-
<b>Total</b>	<b>0.49</b>	<b>-0.39</b>	<b>0.06</b>

Table 7: Shareholder Investment Income 2020

2019 Asset Class	Interest (£m)	Net Gains and Losses (£m)	Unrealised gains and losses (£m)
Government Bonds	0.29	-0.49	0.04
Corporate Bonds	0.07	0.05	-0.02
Collateralised Securities	-	-	-
Cash and Deposits	0.37	-	-
<b>Total</b>	<b>0.74</b>	<b>-0.44</b>	<b>0.02</b>

Table 8: Shareholder Investment Income 2019

### Policyholder Funds

CLIAI solely writes unit-linked business. Policyholder premiums are invested in unit-linked investment funds at the direction of the policyholder and it is the policyholders themselves that bear the risks associated with the underlying assets. Should the underlying assets increase or decrease in value, it is the policyholders who will gain or lose from this through the movement in the policy value.

## A. Business and Performance

The funds in which policyholder premiums are invested are selected by the policyholders themselves, and reflect each individual's personal investment risk preferences. CLIAI's policyholder funds can be broadly split into two categories, as follows:

- **Direct Holdings**; whereby a policyholder directly selects the assets that they want to invest in, and CLIAI uses the policyholder's premium to purchase the assets on the policyholder's behalf; and
- **DFM's**; where a DFM is chosen by the policyholder they invest the funds in a variety of asset classes in line with the policyholder's attitude to risk. CLIAI has a legal agreement in place with each of the DFM's.

**DFM arrangements can fall into two categories:**

- **Standard DFM agreement** – this restricts the DFM to a prescribed list of permitted assets, primarily allowable collectives or cash.
- **Segregated Portfolio Service (SPS)** – an extension of the Standard DFM agreement which allows wider investment options provided strict conditions are adhered to. This is not available to all DFM's. Unlike the standard CLIAI DFM arrangement where the DFM is allowed to engage freely with both the policyholder and their financial adviser, under the SPS option the policyholder and their financial adviser are not allowed to influence the DFM's investment decisions beyond the policyholders disclosing their attitude to investment risk and high level investment objectives. This means that SPS must operate under very strict auditable processes in order to ensure that this condition is not breached.

**An extensive control framework is in place which focuses on a number of key controls including:**

- Asset holdings verification to ensure appropriate asset permissibility under criteria set out by the UK HM Revenue & Customs are fully met; and
- Ensuring policy valuations are in line with expected values.

Quarterly reviews are carried out to ensure that asset identifiers are correct and in existence. Periodic reviews are undertaken to ensure all assets are registered in the name of CLIAI on the DFM systems.

As at year end 2020, CLIAI had £6.7 billion in policyholder funds under management. The table below shows the breakdown of asset types held (considering both Direct Holdings and funds invested with DFM's).

Asset Class	31st December 2020 (£m)	Percentage of overall fund
Collective Funds	5,585.41	83.17%
Cash	520.37	7.75%
Direct Equity	527.69	7.86%
Government Bonds	46.93	0.7%
Collateralised Securities	0.01	0.00%
Corporate Bonds	29.72	0.44%
Property	0.00	0.00%
Structured Notes	5.4	0.08%
<b>TOTAL</b>	<b>6,715.53</b>	

Table 9: Asset by Class

### A.4 Performance of Other Activities

#### Operating Expenses

In the year ending 31st December 2020, the Company reported operating expenses of £13.47m (2019: £15.27m) as per the Financial Statements.

#### Fee Income

For 2020 the Company earned Fee Income of £12.02m (2019: £12.4m), this was driven by a decrease in upfront and ongoing charges offset by increase in administration fee.

#### Leasing

The Company has had no leasing arrangements in place during the reporting period.

## B. Systems of Governance

### B.1 General Information on the System of Governance

The Board of Directors of CLIAI is responsible for the governance and oversight of the risks to which CLIAI is exposed. Risk governance in CLIAI is supported by the Enterprise Risk Management Framework, as described in the Board-approved Enterprise Risk Management Policy. The Board sets risk strategy and risk preferences for CLIAI in relation to the types and level of risk that the Company is permitted to assume in the implementation of its strategic plans.

CLIAI operates a 'Three Lines of Defence' risk governance model. In this model, the first line of defence against risk is maintained by the functional areas of the business. The second line of defence is the oversight and control functions of the business which control, monitor and report risks within the group risk governance structure i.e. risk, actuarial and compliance. The third line of defence includes the independent assurance provided by the Internal Audit function.

The Board has assigned key duties and responsibilities in relation to risk identification, assessment, measurement, monitoring and control to the Board Risk Committee (BRC). The BRC is responsible for providing advice to the Board in its oversight of the Company's principal risks.

#### B.1.1 Risk Governance Structure

The Board of Directors is responsible for ensuring an appropriate system of governance is in place throughout the Company. The Board oversees the implementation of the agreed business strategy for the Company. The Board is responsible for setting and overseeing an adequate and effective internal control framework.

#### CLIAI Board of Directors

There is an effective Board in place to lead and direct the Company. The Board conducts its affairs in compliance with Company law (including the provisions of the Companies Act 2014), the Company's Constitution, the Central Bank's 2015 Corporate Governance Code, and all other applicable laws and regulations. The Board acknowledges the legal duties and obligations imposed on Directors by the Companies Act 2014, other statutes

and common law, including the principal fiduciary duties of directors as set out in Section 228 of the Companies Act 2014, as laid out in the Board's Terms of Reference.

The Board has reserved to itself for decision a formal schedule of matters pertaining to the Company and its future direction, such as the Company's commercial strategy, major acquisitions and disposals, Board membership, appointment and removal of the Managing Director and the Company Secretary, executive remuneration, trading and capital budgets and risk management policies. All strategic decisions are referred to the Board. Documented rules on management authority levels and on matters to be notified to the Board are in place, supported by an organisational structure with clearly defined authority levels and reporting responsibilities.

The Board is currently comprised of 1 executive director and 4 non-executive directors.

As at 31st December 2020, the Board consisted of Mr. Harold Snow (Chair, Non-Executive), Mr. Ian Gilmour (Non-Executive), Mr. Vincent Sheridan (Independent Non-Executive), Ms. Sylvia Cronin (Independent Non-Executive), and Mr. John McNamara (Managing Director, Executive). The Board considers its current size and structure to be appropriate to meet the requirements of the business. While there is no optimum number of non-executive and executive directors, membership of the Board is kept under continuous review.

The roles of the Chair and the Managing Director are separated and in line with the Corporate Governance Code. Procedures are in place for directors, in furtherance of their duties, to take independent professional advice and training, if necessary, at the Company's expense. Appropriate training is arranged for directors on first appointment and the Board also ensures that the directors continually update their skills and knowledge through appropriate seminars and presentations.



## B. Systems of Governance

The Company Secretary is responsible for advising the Board through the Chair on all governance matters. All directors have direct access to the Company Secretary. Any director who has any material concern about the overall corporate governance of the Company must report the concern without delay to the Board in the first instance and if the concern is not satisfactorily addressed by the Board within 5 business days, the director must promptly report the concern directly to the Central Bank of Ireland advising of the background to the concern and any proposed remedial action. This is without prejudice to the director's ability to report directly to the Central Bank of Ireland.

### Board Committees

- The Company has the following Board committees:
  - Board Audit Committee (BAC)
  - Board Risk Committee (BRC)
- The Charters of both the Board Audit Committee and the Board Risk Committee are reviewed annually and kept in line with group standards.

### Board Audit Committee

At 31st December 2020, membership of the Company's Audit Committee comprised Mr. Vincent Sheridan (Chair), Ms. Sylvia Cronin, Mr. Ian Gilmour, Mr. Harold Snow and Mr. John McNamara. The Board ensures that the Chair of the committee has recent and relevant financial experience.

The Audit Committee is responsible for:

- Providing a link between the Board and the external auditors;
- Making recommendations in respect of the appointment of external auditors;
- Reviewing the scope of the external audit;
- Reviewing the Company's annual report and financial statements; and
- The effectiveness of the Company's internal control systems and risk management process.

The Audit Committee monitors the Company's internal audit and considers issues raised and recommendations made by the external auditors and by the Internal Audit function. The committee meets at least annually with the external auditors in a confidential session without management being present. The committee reviews the arrangements by which staff of the company may, in confidence, raise concerns about possible improprieties in matters of financial reporting or other matters.

The Audit Committee reviews the non-audit services provided by the external auditors based on the policy approved by the Board in relation to the provision of such services. Other assurance services are services carried out by the auditors by virtue of their role as auditors and include assurance related work, regulatory returns and accounting advice. In line with best practice, the auditors do not provide services which could be considered to be inconsistent with the audit role.

### Board Risk Committee

At 31st December 2020, the Company's Risk Committee was comprised of Ms. Sylvia Cronin, Mr. Vincent Sheridan (Interim Chair), Mr. Ian Gilmour, Mr. Harold Snow and Mr. John McNamara. The Board ensures that the Chair of the committee has recent and relevant risk experience.

The Risk Committee is responsible for:

- Oversight and advice to the Board on risk governance;
- The current risk exposures of the Company and future risk strategy, including strategy for capital and liquidity management;
- The embedding and maintenance throughout the Company of a supportive culture in relation to the management of risk; and
- Supporting the Board in carrying out its responsibilities for ensuring that risks are properly identified, reported, assessed and controlled, and that the Company's strategy is consistent with the company's risk appetite.

## B. Systems of Governance

The BRC has responsibility for the setting of compliance policies and principles and the embedding and maintenance throughout the Company of a supportive culture in relation to the management of compliance.

The BRC is responsible for monitoring adherence to the Company's Risk Appetite Framework (RAF). Where exposures breach levels established in the RAF, the BRC is responsible for developing appropriate responses. This is facilitated by the quarterly review of compliance with the risk appetite metrics calibrated to the Risk Appetite Framework.

The CLIAI BRC recommends matters as listed in the CLIAI Enterprise Risk Management Policy to the Board for approval. The CLIAI Risk Function reports to the CLIAI BRC through the CLIAI Chief Risk Officer (CRO). The CLIAI BRC's duties are set out in its Charter which is reviewed annually.

In particular, the CLIAI BRC review, assess and approve compliance with:

- The CLIAI RAF, including risk limits and compliance;
- The CLIAI Own Risk and Solvency Assessment (ORSA), including stress and scenario testing;
- CLIAI's risk policies;
- CLIAI's consolidated risk profile; and
- The effectiveness of the CLIAI risk management system.

### **2020 Material changes**

There were no material changes to the governance of CLIAI in 2020.

## B. Systems of Governance

### B.1.2 Key Function Holders

The functional roles within the Company and their responsibilities are as follows:

#### 1. Managing Director

The Managing Director is fully accountable for all operational activities, the delivery of CLIAI's strategy and subsequent implementation as agreed by the CLIAI Board.

#### 2. Head of Actuarial Function

The Head of Actuarial Function (HoAF) is responsible for the Actuarial Function within CLIAI, including the coordination of Solvency II actuarial requirements. The HoAF has oversight responsibilities for actuarial activities including ensuring compliance with related internal policies, professional standards and regulatory guidelines.

#### 3. Head of Finance

The Head of Finance (HoF) has responsibility for the establishment, maintenance and monitoring of sound financial strategy, governance, and reporting for CLIAI. The HoF will also perform any other functions that are delegated to the HoF by the Audit Committee or the Board of the Company.

#### 4. Chief Risk Officer

The primary objective of the Chief Risk Officer (CRO) of CLIAI is to provide independent risk oversight of all risk-taking activities of the Company. This is accomplished by the development and implementation of the CLIAI Enterprise Risk Management Framework. The CRO is responsible for the design and implementation of the risk management system.

#### 5. Company Compliance Officer

The primary objective of the Company's Compliance Officer (CCO) and the compliance management function is to ensure that a good state of compliance is maintained in the Company and to provide information and objective advice on regulatory issues and developments to both the BRC and senior management.

#### 6. Chief Internal Auditor

The Chief Internal Auditor assists the CLIAI Board of Directors, through the Audit Committee, in carrying out its corporate governance responsibilities. A secondary objective is to assist members of CLIAI in the achievement of its goals and objectives in a way which is adequately controlled and effectively managed.

## B. Systems of Governance

### B.1.3 Adequacy of Review and Systems of Governance

The key role and function holders within CLIAI are subject to the Central Bank of Ireland Fitness and Probity Regime. To evidence the appropriateness and effectiveness of their activity, roles may be pre-approved by CBI. The key governance structures i.e. Board, Committees and key function holders, are subject to various internal assessments.

In respect of 2020, each of the key functions presented an effectiveness review at their relevant Board and/or Committee meeting. This is an ongoing annual process which looks at the mandates within each function and assesses their performance against these mandates.

Across the wider Canada Life Group, there is an independent observation process undertaken with respect to Board and Committee meetings with a view to examining their activities and effectiveness. Feedback and recommendations were made to the Board in February 2021 with respect to the 2020 framework. The Board is satisfied that the governance arrangements are appropriate. The arrangements will be kept under continuous review, and refinements will be made in the future as appropriate, including responding to any future regulatory guidelines or emerging best practice.

CLIAI has a Board-approved Diversity policy which has set targets on gender diversity and ensures balanced panels for Board succession and the policy is reviewed on an annual basis. The business forms part of the Diversity and Inclusion strategy across the Irish group businesses and there is regular reporting to Board on progress against the agreed priorities.

### B.1.4 Remuneration Practices

The CLIAI Board has approved the role of the CLIHRC Remuneration Committee to support it in carrying out its remuneration related roles and responsibilities. On an annual basis the CLIHRC Remuneration Committee reviews and approves the Policy, and based on data provided, ensures that there is general compliance with the Policy and is advised of any compliance breaches.

The remuneration programme of CLIAI aims to promote sound and prudent management of the business which ensures that risk is taken within the risk framework as approved by the Board. The principles of the programme are to attract, retain and reward qualified and experienced staff who will contribute to CLIAI's success, motivate its staff to meet the annual corporate and individual performance goals and ultimately to enhance long-term shareholder and policyholder value.

The Remuneration Operating Policy was last approved by the Board in November 2020. The Company utilises the remuneration policy to:

- Support the Company's objective of generating value for shareholders and customers over the long term;
- Motivate employees to meet annual corporate, divisional and individual performance goals;
- Promote the achievement of goals in a manner consistent with the Company's Code of Business Conduct; and
- Align with sound risk management practices and regulatory requirements.

The Remuneration Operating Policy is supported by a performance management process that promotes the development of a high performance culture in line with the Company's vision and values. This process is characterised by the core principles of quality feedback and open conversations, shared responsibility for the process, equitable treatment of staff and acknowledgement of the positive contribution of staff.

The CLIAI remuneration programme consists of four elements – base salary; annual incentive bonus; retirement benefits and benefits during the course of employment. For variable elements of the remuneration programme, target objectives are set annually and are comprised of at least two of the following components:

1. Earnings, expenses and sales targets of the Company and / or a business unit within the Company;
2. Specific individual objectives in support of Company and / or business unit objectives; and
3. Group or Company outcomes.

## B. Systems of Governance

As outlined in the table below, CLIAI Remuneration Programmes consist of four primary elements; the proportion of each element in the overall package will vary based on the role.

Element	Primary Role
Base Salary	Reflect skills, competencies, experience and performance level of the individual, and incorporating assessment against non-financial metrics.
Annual Incentive Bonus	Reflective of performance for the period measured. The appropriate incentive scheme is determined as part of the Job Evaluation process. Where appropriate payment of a proportion of the total bonus may be deferred.
Retirement Benefits	Provide an incentive for staff retention and for a level of replacement income upon retirement.
Benefits during the course of employment	Provide adequate protection in the case of sickness, disability or death. Provide opportunities to share in the long term performance of the Company. Provide a range of benefits to support individual needs.

Table 10: CLIAI Remuneration Programmes

The remuneration policy sets out at a high-level CLIAI's approach to managing the risks associated with how it remunerates or otherwise incentivises its staff while treating its customers fairly and meeting the objectives of the CLIAI Board and its Risk Preferences. It promotes the achievement of goals in a manner consistent with the Company's Code of Conduct, its RAF and in compliance with regulatory requirements.

### Principles for Risk Management

The overall approach for managing the risks relevant to the remuneration policy are those set out in the umbrella policy for Operational Risk and the Great-West Life Code of Conduct.

CLIAI has used this approach to determine its own principles and used them in turn as a reference point to determine the specific approach set out in the remuneration policy.

### The CLIAI remuneration principles are:

1. The remuneration programmes promote sound and effective risk management and align with CLIAI Risk Preferences as approved by the Board;
2. The remuneration programmes are in line with CLIAI business and risk strategy and long term shareholders' interests;
3. The Policy is communicated to staff of CLIAI;
4. The remuneration programmes are competitive and fair;
5. To attract, reward and motivate CLIAI staff to deliver on CLIAI objectives and success; and
6. There is clear, effective and transparent governance in relation to remuneration;
7. The remuneration programmes are consistent with the CLIAI approach to the integration of sustainability risks in the investment decision making and investment advice process.

The Risk Function provides independent oversight of policy implementation through its normal oversight activities and through specific risk reviews and investigations. Key decision makers do not solely benefit from potentially higher risk strategies and the Remuneration Operating Policy reflects that. The CRO is not reliant on CLIAI commercial performance in relation to their remuneration/bonus scheme and instead has a percentage of their bonus attributable to the wider performance of the group.

### Material transactions during reporting period

There were no material transactions in the period.

## B. Systems of Governance

### B.1.5 Control Functions

The Board Committees are supported by dedicated control functions established within the Company. Each of the control functions report to either the Board Audit or Board Risk Committee, and the appropriate Board committee approves the mandate, resources and plans for the control functions on an annual basis. The control functions report to each meeting of the Board committees, and the head of each control function has a direct line of communication with the Chair of the relevant Board committee.

#### Risk Function

The Risk Function supports the Company's CRO in the development of the Risk Appetite Framework, development and ongoing review cycle of risk policies, oversight of risk identification, assessment, management and monitoring/reporting, coordinating the Own Risk and Solvency Assessment (ORSA) and the provision of risk advice to the business. Responsibilities of the CLIAI Risk Function are set out in the CLIAI CRO Mandate. The Risk Function is operationally independent and separate from the business areas of the Company. Responsibilities of the Risk Function are set out in the CRO Mandate.

#### Actuarial Function

The Actuarial Function provides actuarial services and advice to the Company. Led by the HoAF, this function carries out the Company's actuarial-based statutory duties, including the investigation of its financial condition, the valuation of its technical provisions and the review of the sufficiency of premiums for new business. The Actuarial Function monitors the solvency and capital of the Company and supports the Risk Function in determining the capital required to cover the nature and level of the risks to which the Company is, or might be, exposed. Responsibilities of the Actuarial Function are set out in the HoAF Mandate.

#### Compliance Function

The Compliance Function is an integral part of the Internal Control System under Solvency II. Responsibilities of the CLIAI Compliance Function are set out in the CLIAI Compliance Function Mandate. The primary objective of the CCO and the Compliance Function is to ensure that a good state of compliance is maintained and to provide information and objective advice on regulatory issues and developments in relation to the Company, to the BRC and to senior management.

#### Internal Audit

The Internal Audit Function operates in accordance with its BAC-approved mandate. Its objective is to provide an effective and responsive internal audit service that adds value to, and improves the Company's operations.

This service is provided through risk-based, independent assessment of the adequacy, effectiveness and sustainability of the Company's governance, risk management and control processes; with the ultimate objective of providing an opinion on the control environment to the BAC. All activities undertaken within the Company are within the scope of Internal Audit. This includes the activities of other control functions. Internal Audit has unrestricted access at any time to all records, personnel, properties and information of the Company.

#### Finance Function

The Finance Function produces the base capital plan, used for projecting CLIAI's solvency position. The Finance Function is responsible for the production, reconciliation and review of monthly management, quarterly group and annual statutory reporting which encompasses both the shareholder and the policyholder aspects of the business. Responsibilities of the Finance Function are set out in the Finance Function Mandate.

### B.2 Fit and Proper Requirements

CLIAI is committed to ensuring that all of the fit and proper requirements are met by the Company and in this regard, ensures that all persons who effectively run the Company or manage other key functions have the required qualifications, knowledge, skills and experience required to carry out their role (fitness assessment) and are honest, ethical, act with integrity and are financially sound (probity assessment).

There is a job profile in place for all such roles. Typically the job profile will set out the accountabilities for the job, the level of knowledge, skills and experience required to carry out the job, together with the behavioural competencies that are essential for the job.

## B. Systems of Governance

There are documented HR processes in place for recruitment into roles subject to Fitness and Probity requirements. The Company also has in place a Fit and Proper Policy which is reviewed and approved annually by the Board. The Policy sets out the process for fit and proper assessments to be conducted to determine a person's fitness, probity and financial soundness.

Before an appointment is made in respect of persons who effectively run CLIAI or have other key functions within CLIAI, a due diligence process is undertaken to ensure that the person is fit and proper for the role. The due diligence checks for assessing whether a person is fit and proper and is financially sound are set out in the policy. These checks align to the Central Bank of Ireland's Guidance on Fitness and Probity Standards 2015.

In relation to the probity and financial soundness checks, the due diligence is largely by way of self-certification with proposed appointees being requested to complete a questionnaire enquiring as to their probity and financial soundness. The Company then conducts independent directorship and judgements searches.

Most of the roles applicable to persons who effectively run CLIAI are pre-approval controlled functions. In addition to the internal due diligence conducted, in advance of appointments into these functions, there is also a requirement that they are pre-approved by the Central Bank of Ireland.

Adherence to the Fitness and Probity standards and requirements is subject to annual reconfirmation by persons occupying fit and proper roles. Where the Company becomes aware that there may be concerns regarding the fitness and probity of a person in a role subject to the Fit and Proper Policy, the Company will investigate such concerns and take action as appropriate without delay.

The Company will notify the Central Bank of any such action taken where there has been a negative conclusion reached with regard to persons holding a role subject to fitness and probity.

### B.3 Risk Management System Including the 'Own Risk and Solvency Assessment'

The Company's Risk Function is responsible, amongst other things, for:

- Maintaining effective processes to identify, manage and monitor risk across the Company;
- Co-ordinate and report the results of the CLIAI ORSA which is the collection of defined processes, aligning the ERM Framework with capital management and business planning, adhering to the requirements of the CLIAI ORSA Policy;
- Risk reporting in a timely and comprehensive manner to the Risk Committee; and
- Facilitation of the setting of Risk Appetite by the Board.

The Company has a comprehensive Enterprise Risk Management Framework for the purpose of identifying, managing and monitoring risk across the Company as more fully described in the sections below.

The Risk Function is headed by a sufficiently senior resource within the Company, the CRO, considered by the Board as having sufficient authority and independence to effectively discharge the duties of the role. The CLIAI CRO has direct access to the Board and a reporting line to the UK Division, independent of the Executive. In addition, the CLIAI CCO has direct access to the CLIAI CRO for support.

## B. Systems of Governance

### B.3.1 Risk Management Framework – Three Lines of Defence

CLIAI operates a ‘Three Lines of Defence’ model, as illustrated by the diagram below.

	Board of Directors		
First Line of Defence	Second Line of Defence		Third Line of Defence
Board / Executive Management	Board Risk Committee		Board Audit Committee
Business Management	Chief Risk Officer	Risk and Compliance	Local Internal Audit
<p>Document processes</p> <p>Implement appropriate controls</p> <p>Monitor and confirm the operating effectiveness of controls</p> <p>Correct deficiencies</p>	<p>Evaluate appropriateness of the design of overall control framework and the effectiveness of its operation</p>	<p>Oversee compliance with regulatory standards</p> <p>Report deficiencies</p> <p>Support and guide business in documenting processes</p> <p>Support control, design and implementation</p> <p>Verify control confirmation by business and challenge if necessary</p> <p>Report weaknesses</p>	<p>Review the appropriateness and effectiveness of the internal control system on behalf of the Board of Directors</p>

Table 11: Three Lines of Defence

The principles of the three lines of defence model which articulates clear segregation between risk management, oversight and assurance are as follows:

#### First Line of Defence

The first line responsibilities for risk management are generally performed by CLIAI management and staff as it is CLIAI operations where business activities occur and risks are assumed.

#### Second Line of Defence

The CLIAI Risk Function has responsibility for ensuring the consistent and appropriate measurement and reporting of consolidated CLIAI risk exposures, with measurement and reporting practices aligned with CLG

requirements. CLIAI may organise its required risk measurement and reporting as appropriate given its organisational structure, and may produce additional risk measurements to meet its own business, regulatory or risk management requirements. In the event that CLIAI believes that any required CLG risk measurements are inappropriate for the risks of the company, the CLIAI CRO has a reporting line to the UK Division which allows for escalation.

The roles and responsibilities of the CLIAI Risk Function are as follows:

- Maintain a set of risk definitions, consistent with those of CLG and GWL, to ensure that risks across the company are consistently defined and measured;
- Establish consistent methodologies and calibrations for the measurement and aggregation of risks across CLIAI;



## B. Systems of Governance

- Propose the CLIAI level RAF, including calibrations, for approval by the CLIAI Board;
- Establish a CLIAI stress and scenario testing regime including the calibration of the selected stresses;
- Produce consolidated CLIAI risk reporting and scenario testing in collaboration with the CLIAI Actuarial Function;
- Produce a CLIAI ORSA including an assessment of the appropriateness of the standard formula capital requirement for the risks of CLIAI; and
- Report on company level risks such as intra-group transactions, concentrations of risk at the Company, contagion exposures, specific risks such as currency and exposure to reinsurers.

### Third Line of Defence

Internal Audit is a fundamental part of the Risk Management System. Internal audit, as the 3rd line of defence, carries out risk-based independent assessments of the internal risk control framework and the oversight provided by the 2nd line of defence.

Internal Audit is responsible for performing an independent assurance and validation of the operational effectiveness and design of the Enterprise Risk Management Framework. This includes periodic audits of first and second line control processes to help ensure effective and efficient operations, integrity of financial reporting, appropriate information technology processes and compliance with law, regulations and internal policies.

### B.3.2 Enterprise Risk Management (ERM) Framework

Article 44 of the Solvency II Directive states that the Risk Function has a key role in providing oversight of the implementation of the Risk Management System. Article 246 of the Solvency II Directive emphasises consistency in the implementation of the Group System of Governance and that the risk management, internal control systems and reporting procedures should be implemented consistently in all the undertakings included in the scope of group supervision so that those systems and reporting procedures can be

controlled at the level of the group. CLIAI's ERM Framework is designed to ensure that all material risks are identified and managed and that business strategy across the Company is implemented in full recognition of its risks.

The CLIAI ERM Framework consists of five key components and is aligned with the Group ERM Framework, namely:

Risk Appetite Framework	The Risk Appetite Framework articulates the company's Risk Strategy, Risk Appetite Statement and limits.
Risk Policies	The documented and approved risk governance and risk processes for specific identified risks.
Risk Principles and Governance	The principles, roles and responsibilities relating to risk management and governance.
Risk Processes	The risk management, governance and oversight processes, including the ORSA.
Risk Infrastructure	CLIAI's organisational infrastructure is in place to ensure resources and risk systems required to support risk policies, operating standards and guidelines and processes are adequate and appropriate.

### B.3.3 Risk Appetite

#### Risk Appetite

The CLIAI Risk Strategy document includes a comprehensive listing of the risks assumed by CLIAI and CLIAI's preference for each. It is an essential component of this CLIAI Risk Appetite Framework and is maintained as a separate self-contained document. The CLIAI Risk Strategy is reviewed annually by the CLIAI BRC and was approved in Q4 2020 by the CLIAI Board. The Board has satisfied itself that the risk management framework and internal controls reflect the risk appetite and that there are adequate arrangements in place to ensure that there is regular reporting to the Board on compliance with the risk appetite.

## B. Systems of Governance

The Risk Appetite Framework (RAF) is aligned with CLIAI's Risk Strategy, as established in the Risk Strategy document, and encompasses the following elements along with the associated governance structure:

- **Risk Appetite Statement:** The aggregate level and types of risk that the Company is willing to accept in order to achieve its business objectives.
- **Risk Limits:** Translates the Risk Appetite Statement into more specific limits by the defined Risk Types.

Risk limits provide a period-specific quantification of the objectives set out in the Risk Appetite Statement, permitting regular assessment, reporting and monitoring of compliance to the Board. Three levels of Risk Limits exist:

- **Level 1**  
Level 1 limits are a high level overarching statement of risk appetite of the Board - i.e. how big a solvency or liquidity buffer does the Board want to maintain?
- **Level 2**  
Level 2 limits provide constraints on exposure to individual risk types. In setting the Level 2 limits, the Board promotes appropriate diversification of risk across the business, whilst reflecting the strategic plans for CLIAI.
- **Level 3**  
Level 3 limits are drivers of the underlying capital requirements expressed in terms of business metrics which can therefore be more readily understood and applied by management on a day-to-day basis.

Business Functions are responsible for operating within the RAF and, in addition, satisfying regulatory needs as required. In applying the principles laid out in this document, proportionality will be taken into account. The RAF is therefore central to the overall ERM Framework of CLIAI.

### B.3.4 Risk Identification, Assessment and Treatment

Identification of risks within the Company (both existing and emerging) is overseen by the Risk Function. CLIAI uses the standard formula to calculate Solvency II valuation results. Due to the nature of the products, size and resources of the business, an internal model was not considered appropriate.

Should the business see a significant increase in size or the launch of more complex insurance products, then this decision would be reviewed. The standard formula is calculated according to the Solvency II Delegated Regulations.

### Risk Identification and Assessment

The Company has a standard framework for the identification and assessment of risk. The framework comprises a number of segments designed to support the identification and assessment of the range of risks that the Company may be exposed to.

Key CLIAI Processes for the Identification, Assessment and Prioritisation of Risk include:

- Establishing consistent risk definitions to be applied in CLIAI;
- Risk reporting which includes a prospective risk assessment to identify areas where risks could be evolving or emerging due to changes in business strategy or market conditions;
- Risk reporting (supported by risk escalation protocol) to ensure that risks with significant potential to impact CLIAI are escalated for assessment; and
- The Emerging Risk identification and review process which is facilitated by formal emerging risk identification workshops with findings reviewed by the BRC.

CLIAI will maintain first line and second line operating policies, standards and processes to ensure the effective identification, assessment and prioritisation of risks consistent with the CLG ERM Policy and Solvency II requirements.

### B.3.5 Risk Measurement

The CLIAI Risk Function is responsible for overseeing the consistent measurement of risks to facilitate the monitoring of consolidated risk exposure relative to risk appetite and the ongoing assessment of solvency and solvency needs as part of the ORSA process. Standards for consistent aggregation and monitoring of risk exposures are set out in the ORSA and related reporting standards.

## B. Systems of Governance

Measures to ensure consistent aggregation and monitoring of risk exposures include:

- Defined risk monitoring metrics for each key risk sub-type;
- Sensitivity measures are defined for key risks and aligned to the GWL Capital at Risk calibrations;
- Reporting of Solvency II capital requirements by risk type;
- CLIAI defined stress and scenario tests and projections as part of CLIAI ORSA evaluation; and
- Analysis as required to assess the measurement of risk exposures on new products or strategic initiatives evaluated by the CLIAI Board.

CLIAI is responsible for the accurate reporting of risk exposures consistent with the defined measurement criteria and for the ongoing input and review of the CLIAI measurement calibrations and methodologies to ensure their appropriateness.

### **Risk Management**

The CLIAI Board establishes risk limits for each individual risk as part of the Risk Appetite Framework. CLIAI regularly report on risk exposures versus those limits. Risk mitigation will generally be executed by CLIAI management with the support of the CLIAI Risk Function.

### **Risk Monitoring**

Risk exposures are monitored against appetite through quarterly CLIAI risk reports and augmented through emerging risk analysis and thematic reviews.

### **Risk Reporting**

CLIAI must produce quarterly risk reports to the BRC. The key components of the framework for CLIAI risk reporting are as follows:

- Quarterly reporting of risk exposures against limits and risk appetite;
- Stress testing and sensitivity analysis;
- Solvency projections performed annually as part of the forward-looking assessment which feeds into the ORSA process;
- Providing analysis on material/significant issues, events and risks;

- Attestation of compliance of policies and standards; and
- Breach reporting.

The Company has a formal process for identifying key risks. The key risks identified are reviewed and monitored on a regular basis and reported to the BRC.

### **B.3.6 ORSA**

The Own Risk and Solvency Assessment (ORSA) is an annual process of consideration of the Company's current and future capital needs. The ORSA is used by the Company to form its own view on its solvency needs, given its risk profile and business plans. The ORSA process is carried out in line with the Company's Board-approved ORSA policy.

The overall ORSA process is divided into several sub-processes, with each sub-process being addressed at a different stage of the calendar year so as to ensure it is given appropriate consideration.

The ORSA process is driven by the Actuarial and Risk Functions within CLIAI, with:

- Input from other functions as necessary; and
- Oversight from the CLIAI Board.

Initial considerations take place in the first quarter of the year, with the Actuarial and Risk Function assessing the main risk drivers of the Company. The results of this analysis are considered and approved by the Board before the development of the main ORSA report. Given that this is considered earlier in the ORSA process, it gives the Board an early opportunity to comment on the risk profile of the business and the items that may need to be explored within the core ORSA process.

The ORSA report is prepared after the mid-year solvency position has been ascertained, and this position is used as a starting point for the forward looking assessments considered within the ORSA report.

## B. Systems of Governance

Once the mid-year results are finalised, the main ORSA process is initiated, with the following initial steps:

- The Actuarial and Risk Functions engage with the CLIAI senior management team to get a detailed view on the likely activities of the business. Informed by the latest market conditions, ongoing risk monitoring and the consideration of the risk drivers, the Risk Function ascertain what the most material risks are for the business;
- The Risk Function prepares initial thoughts on the key risks where capital is the main means of managing that risk and will note the stresses and scenarios that will assist the Board in determining CLIAI's level of own solvency needs within the ORSA process; and
- The CLIAI Chief Risk Officer / Head of Actuarial Function present the results of the above steps to the Board and invite views on stresses and scenarios that should be considered within the ORSA exercise. Feedback from the Board is then factored into the work required from the Actuarial and Risk Function that will feed into the ORSA report.

The CLIAI Actuarial and Risk Functions then prepare a quantitative analysis, which considers:

- A range of stresses on the mid-year solvency position (central projection);
- A forward-looking assessment of the evolution of the balance sheet, noting planned business volumes and management activities on a best estimate basis; and
- A range of additional scenarios, where the above central projection is subjected to a number of adverse events (sensitivities and scenarios) so as to assess CLIAI's resilience to balance sheet shocks.

The ORSA report is then drafted considering the above results, and the draft report is presented to the Board at an annual workshop. This gives CLIAI management and the Board adequate time to consider the output of the above exercise, challenge its results and note any additional work that is required. It also gives the Board and senior management time to consider the appropriateness of the business plan and assess any actions which may need to be taken.

The ORSA report is then amended in light of the above discussions, with a final report and any actions arising from it being approved in the Q4 Board meeting prior to the end of the financial reporting year.

Assessment of CLIAI's "own solvency needs" is carried out as part of the ORSA exercise. In carrying out this assessment, CLIAI considers a wide range of risks, stresses and scenarios. CLIAI carries out explicit stress and scenario tests in relation to the key risks of the business, where the risk is of a quantitative nature and explicit assessment of the impact of the risk is possible. This assessment is used to inform CLIAI management and the Board of an appropriate preferred Capital range to hold and this level of capital is documented and approved within the ORSA report and is a key element of CLIAI's Capital Management Operating Policy.

It should also be noted that the Board reviews and approves the CLIAI ORSA Operating Policy on an annual basis.

### B.4 Internal Control System

#### B.4.1 Internal Control System

Internal controls are a set of processes which are maintained and carried out by management and all personnel, reviewed by the Board and designed to ensure:

- Compliance with Group policies and standards;
- Reliability and accuracy of financial and non-financial information;
- Compliance with laws and regulations;
- Alignment of the key controls with the key risks; and
- That the level of risk is within the Company's risk appetite.

These processes enable CLIAI to discharge its obligations under the Handbooks of Rules and Guidance issued by the CBI, and the requirements of the Office of the Superintendent of Financial Institutions, the lead regulator of Great-West Life, CLIAI's ultimate parent undertaking.

## B. Systems of Governance

Internal Controls for CLIAI are specified within policies, mandates, charters and other relevant formal documentation, which are reviewed and approved by the Board and its Committees annually. The Board is accountable for the design and operating effectiveness of the system of Internal Controls. Oversight of the appropriateness and effectiveness of the control environment is provided by the CLIAI BAC.

### B.4.2 Compliance Function

The primary objective of the CCO and the Compliance Function is to ensure that a good state of compliance is maintained in CLIAI and to provide information and objective advice on regulatory issues and developments to senior management and to the BRC to allow them to fulfil their respective accountabilities for the Company's compliance. To achieve this objective, the Compliance Function ensures appropriate controls are in place and ensures that there is independent oversight, review and assessment of relevant legal and regulatory obligations across the Company.

The CCO is responsible for oversight of compliance and regulatory risk for CLIAI. The CCO has a direct reporting line and responsibility to the BRC for oversight matters.

### Anti-Money Laundering Reporting Officer

The CCO is also the Anti-Money Laundering Reporting Officer (MLRO) for CLIAI. The MLRO oversees compliance with anti-money laundering and anti-terrorist financing laws and regulations, arranges periodic awareness raising and assessments and completes reports when necessary to relevant authorities.

### Data Protection Officer

The CCO is also responsible for Data Protection in CLIAI. Under GDPR regulations, CLIAI is not mandated to appoint a Data Protection Officer however the role of Data Protection Specialist was introduced in September 2018. Responsibilities of the Data Protection Specialist include:

- Overseeing compliance with applicable data protection laws; and
- Ensuring there are procedures in the business areas for:
  - Handling concerns and complaints from clients;
  - Appropriate handling of subject access requests;
  - Managing the relationship with the Data Protection Commissioner's Office; and
  - Co-ordinating actions as required in the event of breaches with regulatory or legislative requirements.

### B.5 Internal Audit Function

Internal Audit activity is executed within the framework of a risk-based audit plan as approved by the CLIAI BAC, CLIHC BAC and the Canada Life Group BAC on an annual basis. Audits planned for the year are selected from a universe of business processes with a focus on areas considered to be of the highest inherent risk, giving due consideration to the organization's risk management framework. The universe includes all first and second line activities as well as governance processes. In addition to the Annual Audit Plan, a 5-Year plan is also prepared. The 5-Year plan is designed to ensure that appropriate audit coverage is obtained across the universe of business processes on a cyclical basis.

All audit reports are distributed to those members of the organisation who are in a position to take corrective action or ensure that corrective action is taken to address any gaps identified.

Internal Audit prepares quarterly reports to the BAC summarising audit activity in the quarter, identified weaknesses in the internal control environment, inadequacies in compliance with laws and regulations, recommendations to remedy weaknesses and updates to previous recommendations.

Internal Audit is independent of the business management activities of the Company, thus enabling the businesses to carry out their work with full accountability. Internal Audit is not involved directly in revenue generation or in the management and financial performance of any business line.

## B. Systems of Governance

Internal auditors have neither direct responsibility for, nor authority over, any of the activities reviewed, nor does their review and appraisal relieve other persons in the Group of responsibilities assigned to them. Internal auditors are not responsible for developing, revising or installing systems, policies or procedures or for appraising an individual's performance related to operations audited.

The Chief Internal Auditor (CIA) has a direct reporting line and responsibility to the BAC of the Board of Directors for oversight matters.

The BAC of the Board of Directors has sufficient authority to promote independence and to ensure a broad audit coverage and adequate consideration of audit reports.

The BAC annually reviews and approves the mandate of the CIA, reviews and recommends the appointment/removal of the CIA to the boards, annually assesses the performance of the CIA and the effectiveness of the Internal Audit function. The BAC also reviews and approves the organisational and reporting structure, the Internal Audit department budget and resources and through the Chair of the BAC has the authority to communicate directly with the CIA. The CIA maintains direct and unrestricted access to the BAC.

The CIA Mandate, as approved by the BAC, notes that the CIA and Internal Audit Function is independent of the activities that they audit and free from conditions that threaten their ability to carry out internal audit responsibilities in an objective manner. The internal audit activity is free from interference for matters of audit selection, scope, procedures, frequency, timing or report content to permit maintenance of a necessary independent and objective attitude.

### B.6 Actuarial Function

The Actuarial Function provides actuarial services and advice to the Company. The Actuarial Function carries out the Company's actuarial-based statutory duties, including the investigation of its financial condition, the valuation of its Technical Provisions and the review of the sufficiency of

premiums for new business. The Actuarial Function monitors the solvency and capital of the Company and supports the Risk Function in determining the capital required to cover the nature and level of the risks to which the Company is, or might be, exposed.

The team is led by the Head of Actuarial Function (HoAF) and areas of responsibility include:

- **Technical Provisions:**
  - Setting of assumptions and valuation methodology;
  - Review and sign-off of data quality;
  - Calculation of Technical Provisions;
  - Comparison of best estimate versus experience; and
  - Informing the Board of the reliability and adequacy of calculation of Technical Provisions.
- **Opinions:**
  - Providing an opinion on CLIAI's underwriting policy;
  - Providing an opinion on the adequacy of CLIAI's reinsurance arrangements;
  - Providing an opinion on the Technical Provisions; and
  - Providing an opinion on the ORSA.
- **Business:**
  - Contribute to business planning and budgeting; and
  - Reviewing pricing policies and authority limits.
- **Contribution to the risk management system:**
  - Execute the calculation of the Solvency Capital Requirement (SCR) and Minimum Capital Requirement (MCR);
  - Contribute to the Own Risk and Solvency Assessment (ORSA) process; and
  - Contribute to Risk Management of the business.

## B. Systems of Governance

### B.7 Outsourcing

CLIAI takes a prudent and conservative approach to outsourcing, utilising an outsourcing risk management program, including business continuity plans, designed to ensure that no outsourcing arrangement will be entered into if it would entail unacceptable risk exposure.

When ensuring appropriate oversight and safeguards are in place for critical outsourced functions, CLIAI ensures services are monitored and are being delivered in the manner expected and in accordance with the terms of the agreement. Monitoring takes the form of regular, formal meetings with the material service providers and/or periodic reviews of the arrangement's performance measures. At least annually, the service provider is reviewed to assess its ability to continue to deliver the service to the standard and in the manner expected.

#### **Description of the Outsourcing and Supplier Risk Operating Policy**

In the appropriate circumstances, the outsourcing of specific business functions can be used to reduce or control costs, to free internal resources and capital, and to utilise skills, expertise and resources not otherwise available to the company. However, the outsourcing of specific business functions may also expose the company to additional risks, and those risks must be identified and managed. The Outsourcing and Supplier Risk Operating Policy is a Board-approved policy designed to establish the principles and requirements for the management of outsourcing arrangements.

Where functions and activities of CLIAI are outsourced, the Board and its senior management retain ultimate responsibility for such outsourced functions and activities. The Board and senior management retain the necessary expertise to manage outsourcing risks and provide oversight of outsourcing arrangements.

The policy establishes the following general principles in relation to the identification and management of outsourcing risks:

- Outsourcing arrangements are identified and assessed with regards to their materiality;
- Outsourcing arrangements are subject to appropriate approval;
- Proposed service providers for material outsourcing arrangements are subject to a thorough initial and ongoing evaluation of their capability to perform; and
- Outsourcing contracts for material outsourcing arrangements contain certain mandatory terms and conditions.

Material outsourcing arrangements are subject to effective monitoring and control by senior management with oversight from the BRC.

The CLIAI Outsourcing and Supplier Risk Operating Policy also includes guidance on conducting a due diligence review of an external service provider which may include a number of factors such as:

- Experience and technical competence in providing the relevant service;
- Business reputation;
- Complaints and pending litigation; and
- Business strategy.

CLIAI is currently utilising several service providers to undertake critical or important functions on its behalf. Details of the functions and activities they provide, and the jurisdictions they operate in, are shown in the table on page 32:

## B. Systems of Governance

Service Provider	Description of Service Provided	Jurisdiction
CLIS (Canada Life International Services Limited)	Policy Administration and back-office services	Isle of Man
CLAM (Canada Life Asset Management)	Provision of investment management services	UK
IB (Invest Banca Spa)	Provision of banking, investment & tax reporting services	Italy
CLFIS UK (Canada Life Financial Investment Services)	Services in respect of distribution, financial promotion and investment services.	UK
CLGS (Canada Life Group Services Limited)	Intra-group staff provision services	Ireland
ILGS (Irish Life Group Services Limited)	Provision of HR, Legal, accounts payable and other administration services in order to operate its business	Ireland

Table 12: Service Providers

### B.8 Any Other Information

All information is contained in Sections B1-B7.



## C. Risk Profile

CLIAI's main quantitative measurement of risks is via application of the standard formula set out by the Solvency II Directive and Delegated Regulations. The Solvency II standard formula for the calculation of the solvency capital requirement sets out how much capital a company must hold against each of the risks on its balance sheet.

The standard formula comprises a set of individual risk modules aligned to individual risks that a company may be exposed to.

The risk modules are then aggregated to ultimately calculate the SCR for the company. The following graph shows a condensed flowchart of the standard formula SCR including the principal items relevant for CLIAI and its business.




Figure 2: Standard Formula Structure

The more significant risks to which CLIAI is exposed under the standard formula are set out in Sections C1 to C5 below. For each category of risk, CLIAI determines its risk appetite and sets its investment and associated risk policies accordingly.

The standard formula SCR risk profile comprises life underwriting risk, market risk, counterparty default risk and operational risk. At year end 2020, Solvency II assumptions have been updated for market movements and policyholder experience. These updates have impacted the business from a solvency capital and balance sheet perspective.

The updated assumptions have meant that the proportion of Basic SCR which relates to underwriting risk has decreased over the period. The proportion of the Basic SCR that relates to market risk has increased.

Given the nature of CLIAI's book of business, the shareholder assets are not specifically held to back insurance liabilities. The assets are therefore held primarily to meet operational requirements as well as any solvency requirements. These assets are held in cash in bank accounts and in short term high quality bonds; hence market risk exposure arising from these shareholder assets is low. Counterparty default risk is also relatively low as CLIAI operates to minimum credit ratings as part of its shareholder Investment policy/strategy.

The resulting standard formula basic SCR risk profile for CLIAI as at 31st December 2020 is shown below:




Figure 3: Basic SCR Components

## C. Risk Profile

### C.1 Underwriting Risk

As shown in figure 4, the standard formula indicates that, at 31st December 2020, 61% of CLIAI's basic capital requirement is held in respect of underwriting risk. Due to the nature of the business, the key underwriting risks CLIAI is exposed to are Expense risk and Lapse risk. Longevity, Mortality and Catastrophe risks have also been considered, but these risks are not material risks for CLIAI.

It should be noted that CLIAI does not make use of any Special Purpose Vehicle (SPV) with respect to underwriting risk.

#### Expense Risk

Expense risk is the risk of loss, or of adverse change in the value of insurance liabilities, associated with the variability of expenses incurred in acquiring, servicing and maintaining business.

An increase in the level of expenses, whether due to estimation error, inflation being higher than expected or policy volumes being lower than expected, results in a reduction in future profitability and an increase in the provisions required for future expenses.

The standard formula assessment of the amount of capital required to be held for undiversified expense risk has increased by 9% since year end 2019. This increase is a result of the reduction in EIOPA yield curve and strengthening of Euro against Sterling over the year. These impacts were offset somewhat by the expense assumption updates that have been applied.

#### Lapse Risk

The standard formula assessment of the amount of capital required to be held for undiversified lapse risk has increased by 16% since year end 2019. The increased profitability as a consequence of assumption updates made at year end 2020 have resulted in the business becoming more sensitive to lapse risk as defined by the Solvency II standard formula.

### C.1.1 Investment Assets and Prudent Person Principle as applied to Underwriting Risks

Given the nature of CLIAI's book of business, the shareholder assets are not specifically held to back insurance liabilities. While all assets are invested in accordance with the prudent person principle, there are no specific assets held which directly support underwriting risks.

### C.1.2 Underwriting Risk Concentration

CLIAI's book of business is largely UK based, with a small amount (less than 1% of assets under management) in the Italian market. Therefore there is a concentration of risk due to the exposure to a single market. Lapse risk can increase in times of economic uncertainty and as such the business has a concentrated risk exposure to the UK and its economy.

### C.1.3 Assessment and Risk Mitigation Techniques used for Underwriting Risks

CLIAI monitors and controls underwriting risks via various methods, including:

- A risk register is maintained with an assessment performed on a regular basis and reported through to the CRO and BRC;
- Lapse risk monitoring is conducted monthly;
- Experience investigations covering lapse, mortality and expenses are conducted annually; and
- The annual ORSA process that includes stress and scenario testing is used to assess the ability of the business to maintain its SCR and remain solvent under stressed conditions.

## C. Risk Profile

### C.1.4 Risk Sensitivity for Underwriting Risk

As stated in Section C.1.3, the ORSA includes stress and scenario testing for underwriting risks which enables CLIAI to assess the sensitivity to underwriting risks. For the 2020 ORSA, the solvency position at 30th June 2020 and the projected solvency position over the business planning period were re-calculated following a range of adverse stresses for the material underwriting risks including expenses and lapses. Stress tests completed included a 3% and 4% increase in expenses as well as a 5% and 15% mass lapse stress.

Where an increase or decrease in lapse rates to policies was applied, this increase or decrease respectively has a negative impact for the business. The results, as expected, identified that CLIAI is highly sensitive to lapse and expense risk. As noted in section C.1.3, these risks are actively monitored and managed by management.

### C.2 Market Risk

Market risk is the risk that losses will be incurred due to adverse fluctuations in the fair value or future cash flows of financial instruments.

As shown in figure 3, the standard formula indicates that, at 31st December 2020, 37% of CLIAI's basic capital requirement is held in respect of market risk. The key market risks CLIAI is exposed to are equity risk and currency risk. In terms of SCR risk components, CLIAI is also exposed to spread risk, interest rate risk and concentration risk, which are included in the overall calculation of market risk. However these are of lower materiality than equity and currency risk, and so are not discussed further in this report.

### Currency Risk

Currency risk is the potential loss of earnings or capital arising from adverse changes in the value of assets, liabilities and financial instruments due to changes in the level or in the volatility of currency exchange rates.

Currency risk for CLIAI arises due to:

- The majority of CLIAI's revenues are earned in GBP, whereas a portion of expenses are incurred in Euro;
- Some policies are non-GBP denominated; and
- Currency base of Shareholder assets.

The standard formula assessment of the amount of capital required to be held for undiversified currency risk has increased by 41% since year end 2019. This increase is largely driven by changes in the currency composition of policyholder funds and movements in the EIOPA yield curve.

### Equity Risk

Equity risk is the risk of loss, or of adverse change in the value of assets and liabilities, associated with the change in the level or in the volatility of market prices of equities.

CLIAI is indirectly exposed to equity risk due to the impact on charge income from policyholder funds which is connected to the underlying value of policyholders' funds.

The standard formula assessment of the amount of capital required to be held for undiversified equity risk has decreased by 7% since year end 2019. This is mainly driven by movements in the EIOPA yield curve

### C.2.1 Investment Assets and Prudent Person Principle as applied to Market Risks

All assets of CLIAI are invested in accordance with the prudent person principle set out in the Delegated Regulations. Both the policyholder funds and shareholder assets are exposed to market risks.

## C. Risk Profile

The Company aims to maintain a matched unit position in respect of all of its policyholder funds. That is, there should be sufficient units created for each fund at least equal to the number of units allocated to policyholders. This is designed to ensure that the company holds sufficient assets of appropriate nature, term and liquidity to enable it to meet its liabilities to policyholders as they become due. This demonstrates investment practice that is in accordance with the prudent person principle with respect to policyholder funds.

CLIAI invests shareholder assets in assets with a risk profile that CLIAI can properly identify, measure, monitor, manage, control and report, and appropriately take into account in the assessment of its overall solvency needs. All assets are invested in such a manner as to ensure the security, quality, liquidity and profitability of the portfolio as a whole. Again, this investment policy is in accordance with the prudent person principle for shareholder assets.

### C.2.2 Market Risk Concentration

Market concentration risk is a standalone sub-module that feeds into the overall Market Risk SCR calculation. Under the Delegated Regulations, assets held in respect of life insurance contracts where the investment risk is fully borne by the policyholders are not included in the calculation of the market risk concentration sub-module. Therefore, only the shareholder assets are assessed for concentration and a specific capital requirement is calculated and held as part of the overall Market Risk SCR in this regard.

Considering market risk beyond the scope of the market risk module within the standard formula, CLIAI has no material concentrations of market risk exposure. CLIAI's own assets are invested in securities from a broad range of issuers, with limits in place so as to reduce concentration exposure. CLIAI only has indirect exposure to the performance of policyholder funds through the fee income it collects to fund the cost of administration of the business.

### C.2.3 Assessment and Risk Mitigation Techniques used for Market Risks

Currency risk is monitored regularly by management reviewing the exchange rate movements between GBP and EUR (in particular). The currency risk due to EUR exposure is partially mitigated by investment in Euro denominated

assets (cash and bonds). In addition, a risk register is maintained and an assessment of market risk is performed regularly and reported through to the CRO and BRC.

### C.2.4 Risk Sensitivity for Market Risks

CLIAI carries out stress and scenario testing as part of the annual ORSA process which includes stress testing of relevant market risks.

For the 2020 ORSA, the solvency position at 30th June 2020 and the projected solvency position over the business planning period were re-calculated following a range of adverse stresses for the material market risks, currency and equity. The stresses applied were a 20% appreciation of EUR against GBP and a 15% and 20% fall in the value of unit-linked policyholder funds. An additional interest rate stress, which investigated the impact of a downward shift in the yield curve was also applied as part of the ORSA. This stress resulted in a material reduction in CLIAI's level of SCR coverage.

### C.3 Credit Risk

Credit risk is the risk of loss, or of adverse change in the financial situation, resulting from fluctuations in the credit standing of counterparties, issuers of securities and any debtors to which CLIAI is exposed in the form of counterparty default risk, spread risk or market risk concentrations.

Due to the nature of CLIAI's business, the credit risk exposure is mainly in the form of counterparty default risk on shareholder cash accounts as described below. CLIAI is also exposed to credit risk in the form of spread risk and concentration risk on shareholder bonds and deposits. Under the standard formula, both spread risk and concentration risk are modelled as part of the Market Risk SCR component and so are not considered further in this section. As shown in figure 3, the standard formula indicates that, at 31st December 2020, circa 2% of CLIAI's basic SCR requirement is held in respect of counterparty default risk.

Counterparty risk includes default and downgrade risk.

## C. Risk Profile

### C.3.1 Investment Assets and Prudent Person Principle as applied to Credit Risks

Counterparties are selected by taking into account the credit rating and reputation of each entity. Credit ratings are used as a way of properly identifying and managing the risk attached to a counterparty and CLIAI ensures only counterparties with suitable credit ratings are engaged. CLIAI also engages with multiple counterparties when conducting business to limit exposure to concentration risk.

### C.3.2 Credit Risk Concentration

As noted above, credit risk is assessed as part of the Market Risk SCR. For CLIAI, shareholder holdings of corporate bonds and deposits require capital to be held in respect of credit risk. For CLIAI as a whole, credit risk concentration is of low materiality, as limits are in place to ensure the Company will not gain exposure to poorly rated entities.

### C.3.3 Assessment and Risk Mitigation Techniques used for Credit Risk

CLIAI has strict limits on appropriate counterparties for each category of assets. The counterparty limits are regularly reviewed to ensure that they are consistent with CLIAI's available assets and risk appetite.

Credit risk is monitored via regular review of counterparty credit ratings and the analysis of the proportion of assets held with any single counterparty.

### C.4 Liquidity Risk

Liquidity risk relates to the risk arising from an inability to meet obligations as they fall due or an inability to meet such obligations except at excessive cost.

Liabilities to policyholders are matched by segregated assets such that there should be sufficient units created for each fund at least equal to the number of units allocated to policyholders. This is designed to ensure that the Company holds sufficient assets of appropriate nature, term and liquidity to enable it to meet its liabilities to policyholders as they become due. Consequently CLIAI's main exposure to liquidity risk relates to shareholder assets. As shareholder investments are in Cash or strongly rated (near liquid bonds), liquidity is not a significant risk for CLIAI.

### C.4.1 Investment Assets and Prudent Person Principle as applied to Liquidity Risks

The investment assets are prudently invested taking into account the liquidity requirements of the business and the nature and timing of the insurance liabilities. The shareholder assets are invested in suitable credit quality holdings which tend to be highly liquid.

### C.4.2 Liquidity Risk Concentration

While liquidity risk is immaterial for CLIAI, concentration of risk could arise due to the relatively small number of counterparties with which shareholder assets are held. However, all shareholder investments are made with counterparties of suitable credit ratings and this acts to limit any potential liquidity risk pertaining to these assets.

## C. Risk Profile

### C.4.3 Assessment and Risk Mitigation Techniques used for Liquidity Risk

CLIAI has a limited appetite for liquidity risk and seeks to mitigate the risk wherever possible.

CLIAI may become financially exposed where a policyholder's assets become impaired; that is, become illiquid or more complicated to price such that its value cannot be properly verified. Should assets become impaired, there may be a requirement for CLIAI to delay calculating surrender values or switch values. This may result in a delay in dealing with any such surrender or switch request. Where such a situation does occur, CLIAI seeks to minimise any impact and will seek to advise the policyholder of the situation and planned actions as soon as is feasible.

Shareholder assets are required to cover the following:

- Commissions and other acquisition expenses;
- Ongoing operating expenses; and
- Coverage of additional reserves and solvency requirements.

CLIAI management monitors liquidity, in appropriate currencies, on a regular basis to ensure that adequate liquid assets are available to allow the company to meet these liabilities as they arise. Assets are invested for appropriately short durations in liquid assets.

### C.4.4 Risk Sensitivity for Liquidity Risk

Given the investment strategy with respect to shareholder assets, that is, investing in short duration liquid assets, there is an immaterial exposure to liquidity risk. CLIAI has the financial resources available to fulfil current and future liabilities based on the current book of business. Therefore, specific sensitivities were not required or carried out as part of the ORSA process.

### C.4.5 Additional Information for Liquidity Risk

Due to the nature of the business, selling single premium policies only, there are no future premiums on the book and hence no expected profit included in future premiums is included.

### C.5 Operational Risk

Operational risk arises from potential problems due to inadequate or failed internal processes, people and systems or from external events. Exposure to operational risk results from either normal day-to-day operations or an unanticipated event and can have material financial and/or reputational consequences for the business.

Operational Risk is comprised of several components, specifically:

- Fraud Risk
  - External Fraud Risk
  - Internal Fraud Risk
- Infrastructure Risk
  - Physical Safety Risk
  - Business Continuity Management Risk
  - Information Technology & Cyber Risk
- Legal & Regulatory Risk
  - Regulatory Compliance Risk
  - Legal Risk
- Supplier Risk
  - Internal Suppliers Risk
  - External Suppliers Risk
- People Risk
  - Diversity & Discrimination Risk
  - Recruitment & Retention Risk
  - Resource Management Risk
  - Remuneration Risk
- Process Risk
  - Aggregation & Reporting Risk
  - Business Processing Risk
  - Modelling Risk
  - Change Management Risk

## C. Risk Profile

Sections C1-C4 above deal with the assessment of the Basic Solvency Capital Requirement (Basic SCR or BSCR). Operational risk is combined with the Basic SCR and any required adjustment (specified under the standard formula) to calculate the overall SCR. The operational risk comprises circa 5% of the overall SCR.

### C.5.1 Investment Assets and Prudent Person Principle as applied to Operational Risks

While all assets are invested in accordance with the prudent person principle, there are no specific assets held which directly support operational risk.

### C.5.2 Operational Risk Concentration

CLIAI's business operations is largely located in a single Group campus in Dublin with an additional element of outsourced operations, administration of policies and investment administration activities in the Isle of Man, and so the servicing of policies is centred in these locations. The associated concentration risks are partially mitigated through business continuity planning and off-site centres for data backup and restoration should an incident occur at either campus.

### C.5.3 Assessment and Risk Mitigation Techniques used for Operational Risk

CLIAI identifies risk exposures and then prioritises and develops risk mitigation strategies to address these exposures.

Operational risk monitoring relates to overseeing and tracking the operational risk profile of the business on an ongoing basis.

CLIAI has processes in place to monitor operational risk exposures against the Operational Risk Management Policy and the RAF.

### C.5.4 Risk Sensitivity for Operational Risk

Operational risk was specifically considered in the 2020 ORSA process through a range of 4 scenarios all quantitative and qualitative in nature. These include a

- Outsourcing - Business Processing Scenario
- Operational Resilience / Pandemic Scenario / Cyber
- Regulatory – Anti-Money Laundering/Counter Terrorist Financing (AML/CTF) Scenario
- Legal / Regulatory – Data

The impacts under consideration were the direct costs of operational losses such as the legal costs, regulatory fines, productivity costs, administrative costs and compensation where applicable.

### Protection Scenario

With regard to new business volumes, a case was considered where the business closes to new business. This scenario sees the projected SCR coverage increase over the beginning of the projection period. This is due to assumed distribution expenses ceasing, however this would not be sustainable in the long term as expense of maintaining closed book of policies would exceed income.

The reverse stress test was structured to combine a number of factors that saw regulatory solvency just breached. This included a mass lapse event, expenses increasing and an increase in inflation. This approach enables management to understand the risk factors that could lead to a significant fall in SCR coverage and hence develop plans to mitigate these risks.

## C. Risk Profile

### C.6 Other Material Risks

CLIAI's most material risks are covered in the above paragraphs. There is a more comprehensive list, the risk universe, which is documented within the Risk Strategy Policy and considered as part of the Company's Risk Appetite Framework. In addition, other risks of the business are explicitly considered in the annual ORSA process.

Throughout 2020, the following issues rose in prominence, were reviewed, and are being monitored on a frequent basis by senior management and the Board:

- Brexit, and related issues;
- Pandemic Risk;
- Cyber and Information Services;
- Project Risks including those related to the growth strategy of the business;
- Climate Change and the consequences of dealing with the results i.e. trapped assets;
- Population change in Ireland, UK and Europe and the future customer base;
- Marrying the advance of technology with developments in the Company's product offering; and
- Data (e.g. Cars/driving statistics, Fitbit watches) and Cyber risk.

#### Cyber Risk

Over the last two years there have been extensive upgrades, detection and prevention tools implemented through the cyber programme. To date there has been no major cyber-attack or data loss event reported. There are numerous automated and manual controls in place to detect, prevent and reduce risk.

In terms of the Information Services Function on the campus and in line with the 3 lines of defence model, it is the 2nd line of defence's responsibility to oversee and provide independent oversight and challenge across the 1st line area. The 3rd line of defence will provide independent assurance of process effectiveness and adherence.

### C.7 Any Other Information

#### Coronavirus Outbreak 2020

- Despite market disruption the impact of Coronavirus from an Operational perspective has been limited to date. The Company has moved to a 100% remote working environment in response to the latest government and group guidelines with the exception of restricted access to the Company's offices for designated staff at specific times to carry out a small number of critical processes.
- We remain focused on providing a safe workplace for our employees and servicing our policyholders without interruption.
- We continue to actively monitor the coronavirus; and assess potential impacts on the entity, and associated financial risks. The market volatility experienced to date does not materially impact the Company in the short term with investment risk borne by the policyholder and standard fee income levels not affected by policyholder asset values. In the longer term, impacts on new business and lapse volumes will be influenced by the progression of the economic disruption over the coming months.

#### Brexit

- This risk has been well considered for over 3 years and the business is comfortable with our position.
- CLIAI's post-Brexit operating model is in place, compliant with the requirements working as envisaged.



## D. Valuation for Solvency Purposes

### D.1 Assets

As at 31st December 2020, the asset value for each material asset type on the Company's Solvency II Balance Sheet is found in the table below:

Asset Type	31st December 2020 (£m)
Government Bonds	23.16
Corporate Bonds	1.07
Collective Investment Undertakings	0.10
Assets held for index-linked and unit-linked contracts	6,715.50
Cash and cash equivalents	16.83
Any other assets, not elsewhere shown	0.43
<b>Total assets</b>	<b>6,757.10</b>

Table 13: Material Solvency II assets (Extract from Appendix)

There have been no changes to the recognition or valuation bases used or on estimates during the reporting period.

#### Bonds

The majority of shareholder bond investments are government bonds with a number of high quality corporate bonds. An investment mandate is in place with Canada Life Asset Management (CLAM) which governs the management of the shareholder bond portfolio. Bond prices are sourced from Thomson Reuters. There are no differences between Solvency II recognition and EU-IFRS.

#### Assets held for Index-linked and Unit-linked contracts

Assets held for Index-linked and Unit-linked contracts are policyholder funds. The valuation of policyholder funds is provided by Thompson Reuters, for direct business, and by underlying DFM's. There are no differences between Solvency II recognition and EU-IFRS.

#### Cash and cash equivalents

There are no differences between Solvency II recognition and EU-IFRS.

#### Any other assets, not elsewhere shown

Any other assets, not elsewhere shown represents prepayments, intercompany receivables, income tax receivables and deposit interest due.

### D.1.1 Overview of Methodology for Valuing Assets

#### Valuation

The Technical Specification (EIOPA 14/209) indicates that the Solvency II default reference framework for valuing assets and liabilities, other than technical provisions, should be, unless otherwise stated, the international accounting standards as adopted by the European Commission in accordance with Regulation (EC) No 1606/2002. In most cases those international accounting standards (EU-IFRS) are considered to provide a valuation consistent with Principles of Solvency II.

CLIAI recognises assets and liabilities in accordance with EU-IFRS for its annual Financial Statements and Central Bank guidelines for its regulatory reporting.

As required under IFRS 13, Fair Value Measurement, CLIAI's annual audited Financial Statements disclose the asset and liability valuation techniques used across levels 1, 2 and 3 (i.e. the fair value hierarchy).

A brief description of each 'Level' is set out below:

- **Level 1:** fair value measurements derived from quoted market prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date.
- **Level 2:** fair value measurements derived from inputs other than quoted prices included within level 1 that are observable for the asset or liability either directly (i.e. as prices) or indirectly (i.e. derived from prices).
- **Level 3:** fair value measurements derived from valuation techniques that include inputs for the asset and liability that are based on unobservable market data.

#### Recognition

As a financial reporting regime, EU-IFRS is focused not only on reporting the financial position at the balance sheet date but also on reporting performance in the period. This gives rise to some of the differences between reporting under Solvency II and EU-IFRS.

## D. Valuation for Solvency Purposes

Under Solvency II all assets and other liabilities are reported at economic (fair) value. Where the EU-IFRS valuation is also based on fair value the valuation bases will be aligned. However, in some areas Solvency II introduces different valuation bases where EU-IFRS is not viewed as representing an economic valuation.

EU-IFRS permits the explicit deferral of acquisition costs and income, through the establishment of a notional Deferred Acquisition Costs (DAC) asset and a notional Deferred Income Reserve (DIR) liability.

There is no equivalent concept of deferring revenue or costs over the life of the contract under Solvency II. Therefore, DAC of £4.54m and DIR of £19.05m were written off (to nil value) on the Solvency II balance sheet at the 31st December 2020.

Under EU-IFRS, Goodwill is recognised as a specific asset when an acquisition takes place and there is a positive difference between the purchase consideration paid and the fair value of the net assets acquired. Under Solvency II no value can be ascribed to acquired Goodwill.

### Information on deferred tax assets and liabilities

Per Article 15 of the Solvency II Delegated Acts, deferred tax shall be accounted for as follows. The Company shall recognise and value deferred taxes in relation to all assets and liabilities, including technical provisions. The Company shall value deferred taxes, other than deferred tax assets arising from the carry forward of unused tax credits and the carry forward of unused tax losses, on the basis of the difference between the values ascribed to assets and liabilities recognised and valued in accordance with Article 75 of Directive 2009/138/EC and in the case of technical provisions, in accordance with Articles 76 to 85 of that Directive and the values ascribed to assets and liabilities as recognised and valued for tax purposes.

The Company shall only ascribe a positive value to deferred tax assets where it is probable that future taxable profit will be available against which the deferred tax asset can be utilised, taking into account any legal or regulatory requirements on the time limits relating to the carry forward of unused tax losses or the carry forward of unused tax credits.

Total unutilised losses for which no deferred tax asset has been recognised amount to £30.47m.

At year end 2020 the Company established a tax asset for current tax losses valued at £0.01m. An agreement is in place whereby CLIAI surrendered tax losses to Canada Life Assurance Europe plc, a company in CLIAI's tax group which has taxable profits against which these losses can be offset. CLIAI will receive a cash settlement in exchange for surrendering the tax losses. The £0.01m is reflected in 'Any other assets, not elsewhere shown' (Appendix).

### D.2 Technical Provisions

Technical Provisions as at 31st December 2020:

Technical Provisions – index-linked and unit-linked	31st December 2020 (£m)
TP's calculated as a whole	6,715.50
Best Estimate Liability	-28.70
Risk Margin	16.99

Table 14: Technical Provisions (extract from Appendix)

### Calculation methods

The best estimate liability corresponds to the expected present value of future cashflows discounted using risk-free interest rates. It is an estimate using assumptions described below of the expected profit that CLIAI will earn over the lifetime of the policies in force at the valuation date.

The risk margin is a regulatory prescribed additional technical provision that the Company must hold. There is a cost to holding the SCR. The risk margin is the cost of holding the SCR over the Company's lifetime.

In accordance with Article 58(a) of the Delegated Acts a simplification is used when calculating the risk margin. Under this simplified approach the risks which drive each component of the SCR calculation are used to project the full SCR for each future year.

## D. Valuation for Solvency Purposes

### Assumptions

The below table sets out the assumptions used in the calculation of the technical provisions and hence SCR.

Economic – Best Estimate	31st December 2020
Reference Curve for Discounting and Future Investment Returns	EIOPA swap rate curves – GBP, EUR and USD
Inflation – Expenses & Policy Fees	2%
Other Technical Assumptions – Best Estimate	31st December 2020
Currency of Policyholder Funds	Determined with reference to analysis of underlying policyholder assets.
Type of Policyholder Fund Assets	Assumptions derived based on asset look-through information.
Mortality	Industry standard mortality tables adjusted in light of experience investigations carried out by the Actuarial Function.
Surrender Rates	Observed rates, derived from experience studies carried out by the Actuarial Function.
Expenses	The majority of expenses are estimated from recent internal expense investigation based on experience and are expressed as maintenance expense per policy. Likely future changes in the business are taken into account.

Table 15: Assumptions

Over the period, most of the assumptions remained relatively stable, apart from per policy expense assumptions which decreased due to an increase in policy numbers (the increase in policy numbers is not as significant as previous years due to reduced sales in 2020) and relatively stable cost base. In addition, some refinements have been made to our assumptions and methodology.

### Level of uncertainty associated with the amount of Technical Provisions (TP's)

In assessing the TP's, the actuarial models project cashflows using deterministic assumptions, which are the expected amounts on a best estimate basis allowing for uncertainties in both timing and quantum.

The inherent uncertainty in the actual outcomes arising from the insurance obligations and uncertainty in the estimation of the technical provisions for CLIAI's business is identified by considering how experience deviates from assumptions over time, which is considered as part of the regular review of assumptions and this is used to inform the annual assumption setting process. CLIAI's business and technical provisions are most sensitive to lapse, expense and currency assumptions.

There is no material difference with the valuation basis, method and assumptions used for calculation of technical provisions as a whole in the financial statements. The financial statements are prepared on an EU-IFRS basis and both EU-IFRS and Solvency II are calculated on a best estimate basis.

## D. Valuation for Solvency Purposes

### D.3 Other Liabilities

Other liabilities included in the Solvency II balance sheet at 31st December 2020 are as follows:

Liabilities	31st December 2020 (£m)
Insurance and intermediaries payables	10.71
Payables (Trade, not insurance)	1.85

Table 16: Other Liabilities (extract from Appendix)

The valuation of Insurance and Intermediaries payables and Payables (trade, not insurance) under Solvency II is consistent with the EU-IFRS valuation basis. There has been no changes to the recognition or valuation bases used or on estimates during the reporting period.

#### Insurance and Intermediaries payables

Insurance and Intermediaries payables represent commissions, payables to segregated funds, unapplied premium and claims agreed but not yet paid to policyholders.

#### Trade payables

Trade payables is the balance of agreed but not yet paid amounts billed to CLIAI by its suppliers for goods delivered to or services consumed by the Company in the ordinary course of business.

### D.4 Alternative Methods for Valuation

No alternative valuation methods were used.

### D.5 Any Other Information

Transitional provisions on the risk-free interest rate term structure have not been utilised by CLIAI.

No application has been made in respect of Matching Adjustment, Volatility Adjustment or Transitional Measures on Technical Provisions by CLIAI.

Currently there is no reinsurance of CLIAI's death benefit risk (typically an additional 1% of fund value is payable on death) and it is not proposed to reinsure this benefit. This amount of risk is consistent with the Board's Risk Appetite Statements and so no risk transfer is considered necessary. CLIAI does not make use of any Special Purpose Vehicles.

## E. Capital Management

### E.1 Own Funds

CLIAI's Capital Management Policy and Market and Liquidity Policy are designed to ensure that capital management and liquidity in the Company is aligned with its strategic objectives, the scale and nature of its business and its risk profile. These policies ensure that the Company has sufficient capital, reserves and liquidity to meet its liabilities as they fall due in a range of stressed scenarios and to meet regulatory solvency requirements. The Company's reserves are set in accordance with the conditions set out in the Pricing, Underwriting and Reserving Operating Policy.

CLIAI carries out its Own Risk and Solvency Assessment (ORSA) on an annual basis, and this process is executed in line with CLIAI's Board-approved ORSA Policy. The planning horizon employed within the ORSA is 5 years and throughout this planning period CLIAI considers the nature and quality of its projected Own Funds. Insurers are required to hold additional capital to cover the risk of their assets not being sufficient to cover its liabilities.

Under Solvency II, the main capital requirement is the Solvency Capital Requirement (SCR). There is also a lower Minimum Capital Requirement (MCR). Under Solvency II, capital is referred to as 'Own Funds', divided into 'Basic Own Funds' (held balance sheet amounts) and 'Ancillary Own Funds' (such as letters of credit and guarantees), which require supervisory approval before they can be considered as the own funds of an Insurance entity.

#### Basic Own Funds

The Basic Own Funds consist of (i) the excess of assets over liabilities, and (ii) subordinated liabilities. Examples of basic own-fund items are paid-up share capital, share premium reserve and the reconciliation reserve.

The S.23.01 QRT (Appendix) provides an analysis of the structure of own funds by type and by tier. The four lines, analysed by tier, are:

- Ordinary Share Capital (gross of own shares);
- Share premium account related to ordinary share capital;
- Reconciliation reserve; and
- Other own fund items approved by the supervisory authority as basic own funds not specified above.

The QRT output template has been agreed to the Financial Statements, Solvency II balance sheet and/or applicable back up actuarial schedules.

Basic Own Funds	31st December 2020 (£m)	Tier 1 unrestricted
Ordinary share capital (gross of own shares)	1.37	1.37
Share premium account related to ordinary share capital	5.53	5.53
Reconciliation reserve	-17.94	-17.94
Other own fund items approved by the supervisory authority as basic own funds not specified above	51.80	51.80
<b>Total Basic Own Funds</b>	<b>40.76</b>	<b>40.76</b>

Table 17: Basic Own Funds (extract from Appendix)

#### Ancillary Own Funds

Ancillary Own Funds consist of items other than Basic Own Funds which can be called up to absorb losses. These are therefore items that have not yet been paid in or called up. The company has no ancillary own funds.

## E. Capital Management

### Reconciliation Reserve

The reconciliation reserve represents reserves (e.g. retained earnings) net of adjustments (e.g. foreseeable distributions). It also reconciles differences between the accounting valuation and Solvency II valuation.

A summary of the movements has been provided in the table below.

Solvency II Own Funds to Financial Statements Shareholder Equity	31st December 2020 (£m)
Shareholder Funds as per Financial Statements at 31.12.2020	14.53
<b>Consolidated Retained Earnings</b>	<b>14.53</b>
<b>Adjustments:</b>	
Deferred acquisition costs	-4.54
Deferred income reserve	19.05
Best estimate liability	28.70
Risk margin	-16.99
<b>Solvency II Own Funds</b>	<b>40.75</b>

Table 18: Reconciliation Reserve

Available and eligible own funds	31st December 2020 (£m)
Total available own funds to meet the SCR	40.75
Total available own funds to meet the MCR	40.75
Total eligible own funds to meet the SCR	40.75
Total eligible own funds to meet the MCR	40.75

Table 19: Available and eligible own funds (extract from Appendix)

The eligible amount of own funds to cover the SCR is £40.75m, all are classified as Tier 1.

The eligible amount of basic own funds to cover the MCR is £40.75m, all are classified as Tier 1.

Differences between the Solvency II Own Funds and the Own Funds figures shown in the EU-IFRS financial statements at 31st December 2020 relate solely to the Reconciliation reserve calculations, which vary in line with the changes in actuarial provisioning as follows:

- Elimination of DAC;
- Elimination of DIR;
- Inclusion of Best Estimate Liability; and
- Inclusion of Risk Margin.

### Own Funds – Additional Information

No Own Funds items are subject to any transitional arrangements.

No items have been deducted from Own Funds and there are no significant restrictions affecting the availability of Own Funds as reported.

All Capital contributions were approved in line with CBI Information Note 1 as specified in Article 308a.

## E. Capital Management

### E.2 Solvency Capital Requirement and Minimum Capital Requirement

CLIAI used the Standard Formula to calculate the Solvency Capital Requirement. The results at 31st December 2020 are as follows:

Market Risk	£m
Interest Rate	1.63
Equity	6.02
Property	0.02
Spread	0.21
Currency	8.32
Concentration	0.04
<i>Market Risk Correlation Benefits</i>	-4.27
<b>Total Market Risk</b>	<b>11.95</b>
Life Underwriting Risk	
Mortality	0.23
Longevity	0.05
Disability / Morbidity	0.00
Lapse	12.41
Expense	9.96
Catastrophe	0.02
<i>Life Underwriting Risk Correlation Benefits</i>	-3.20
<b>Total Life Underwriting Risk</b>	<b>19.46</b>
<b>Counterparty Default Risk</b>	<b>0.66</b>
<b>Operational Risk</b>	<b>1.56</b>
<i>Overall Correlation Benefits</i>	6.60
<b>Total Solvency Capital Requirement</b>	<b>27.03</b>
<b>Minimum Capital Requirement</b>	<b>12.16</b>

Table 20: Solvency Capital Requirement and Minimum Capital Requirement

CLIAI does not use simplified calculations or company-specific parameters.

CLIAI has not had any capital add-ons imposed to date.

The MCR is calculated in accordance with the standard formula. That is:

MCR Linear      0.7% of Technical Provisions excluding Risk Margin  
+ 0.07% of Capital at Risk

The Linear MCR is subject to a floor and a cap as follows:

MCR Floor      25% of the calculated SCR.  
MCR Cap      45% of the calculated SCR.

The final MCR calculation is also subject to an absolute floor of €3.7m.

## E. Capital Management

The following table illustrates the principal drivers of the change in the SCR and MCR between year end 2019 and year end 2020.

SCR and MCR Movements	SCR £m	MCR £m
<b>Year End (31/12/2019)</b>	<b>24.01</b>	<b>10.81</b>
<b>Methodology Changes</b>		
Model refinements	0.00	0.00
<b>Impact of Market Movements</b>		
Revised FX rates	0.27	0.12
Revised Interest Rates	1.33	0.60
Movement in Shareholder Assets	0.16	0.07
Other Market Movements	1.40	0.63
<b>Assumption Changes</b>		
Assumption Updates	-0.95	-0.43
<b>Policyholder movements</b>		
New Business and Surrenders	1.24	0.56
<b>Other (including profit/loss in period)</b>	<b>-0.44</b>	<b>-0.20</b>
<b>Year End (31/12/2020)</b>	<b>27.03</b>	<b>12.16</b>

Table 21: Movement in SCR and MCR year end 2019 and year end 2020

The most material movement over the period was caused by market movements such as the decrease in interest rates as well as increased returns on unit funds in the second half of the year. Assumption updates have reduced the overall SCR and MCR, with expense assumptions impacts being somewhat offset by lapse assumption updates.

CLIAI has not used any simplifications in the calculation of the standard formula SCR.

### E.3 Use of the Duration-based Equity Risk Sub-Module in the Calculation of the Solvency Capital Requirement

Not applicable.

### E.4 Differences between the Standard Formula and any Internal Model Used

Not applicable.

### E.5 Non-compliance with the Minimum Capital Requirement and Non-Compliance with the Solvency Capital Requirement

CLIAI has remained compliant with both the MCR and SCR requirement to date.

CLIAI has established procedures for regular monitoring of the SCR with the following escalation limits:

- A management trigger limit of 130%; and
- A Board interaction trigger limit of 125%.

A range of capital measures to take corrective action may be triggered as a result of breaching these limits. This forms part of the Capital plan of the business, where the Board agreed a preferred Capital range of 130-145% of SCR.

### E.6 Any Other Information

The principal loss absorption mechanism does not apply to CLIAI's Basic Own Funds.



## F. Appendix

S.02.01.02 Balance sheet		Solvency II value
	Assets	C0010
R0010	Goodwill	0
R0020	Deferred acquisition costs	0
R0030	Intangible assets	0
R0040	Deferred tax assets 0	
R0050	Pension benefit surplus	0
R0060	Property, plant & equipment held for own use	0
R0070	Investments (other than assets held for index-linked and unit-linked contracts)	24,334
R0080	Property (other than for own use)	0
R0090	Holdings in related undertakings, including participations	0
R0100	Equities	0
R0110	Equities – listed	0
R0120	Equities – unlisted	0
R0130	Bonds	24,227
R0140	Government Bonds	23,158
R0150	Corporate Bonds	1,069
R0160	Structured notes	0
R0170	Collateralised securities	0
R0180	Collective Investments Undertakings	107
R0190	Derivatives	
R0200	Deposits other than cash equivalents	0
R0210	Other investments	0
R0220	Assets held for index-linked and unit-linked contracts	6,715,505
R0230	Loans and mortgages	0
R0240	Loans on policies	0
R0250	Loans and mortgages to individuals	
R0260	Other loans and mortgages	
R0270	Reinsurance recoverables from:	0

## F. Appendix

S.02.01.02 Balance sheet		Solvency II value
	Assets	C0010
R0280	Non-life and health similar to non-life	0
R0290	<i>Non-life excluding health</i>	
R0300	<i>Health similar to non-life</i>	
R0310	Life and health similar to life, excluding index-linked and unit-linked	0
R0320	<i>Health similar to life</i>	0
R0330	<i>Life excluding health and index-linked and unit-linked</i>	0
R0340	Life index-linked and unit-linked	0
R0350	Deposits to cedants	0
R0360	Insurance and intermediaries receivables	
R0370	Reinsurance receivables	
R0380	Receivables (trade, not insurance)	
R0390	Own shares (held directly)	0
R0400	Amounts due in respect of own fund items or initial fund called up but not yet paid in	0
R0410	Cash and cash equivalents	16,833
R0420	Any other assets, not elsewhere shown	431
R0500	<b>Total assets</b>	<b>6,758,102</b>

## F. Appendix

S.02.01.02 Balance sheet		Solvency II value
	Liabilities	C0010
<b>R0510</b>	Technical provisions - non-life	0
<b>R0520</b>	Technical provisions - non-life (excluding health)	0
<b>R0530</b>	<i>TP calculated as a whole</i>	0
<b>R0540</b>	<i>Best Estimate</i>	0
<b>R0550</b>	<i>Risk margin</i>	0
<b>R0560</b>	Technical provisions - health (similar to non-life)	0
<b>R0570</b>	<i>TP calculated as a whole</i>	0
<b>R0580</b>	<i>Best Estimate</i>	0
<b>R0590</b>	<i>Risk margin</i>	0
<b>R0600</b>	Technical provisions - life (excluding index-linked and unit-linked)	0
<b>R0610</b>	Technical provisions - health (similar to life)	0
<b>R0620</b>	<i>TP calculated as a whole</i>	0
<b>R0630</b>	<i>Best Estimate</i>	0
<b>R0640</b>	<i>Risk margin</i>	0
<b>R0650</b>	Technical provisions - life (excluding health and index-linked and unit-linked)	0
<b>R0660</b>	<i>TP calculated as a whole</i>	0
<b>R0670</b>	<i>Best Estimate</i>	0
<b>R0680</b>	<i>Risk margin</i>	0
<b>R0690</b>	Technical provisions - index-linked and unit-linked	6,703,786
<b>R0700</b>	<i>TP calculated as a whole</i>	6,715,505
<b>R0710</b>	<i>Best Estimate</i>	-28,705
<b>R0720</b>	<i>Risk margin</i>	16,986
<b>R0730</b>	Other technical provisions	0
<b>R0740</b>	Contingent liabilities	0
<b>R0750</b>	Provisions other than technical provisions	0
<b>R0760</b>	Pension benefit obligations	0
<b>R0770</b>	Deposits from reinsurers	0

## F. Appendix

S.02.01.02 Balance sheet		Solvency II value
	Liabilities	C0010
<b>R0780</b>	Deferred tax liabilities	0
<b>R0790</b>	Derivatives	0
<b>R0800</b>	Debts owed to credit institutions	0
<b>ER0801</b>	Debts owed to credit institutions resident domestically	
<b>ER0802</b>	Debts owed to credit institutions resident in the euro area other than domestic	
<b>ER0803</b>	Debts owed to credit institutions resident in rest of the world	
<b>R0810</b>	Financial liabilities other than debts owed to credit institutions	0
<b>ER0811</b>	Debts owed to non-credit institutions	
<b>ER0812</b>	Debts owed to non-credit institutions resident domestically	
<b>ER0813</b>	Debts owed to non-credit institutions resident in the euro area other than domestic	
<b>ER0814</b>	Debts owed to non-credit institutions resident in rest of the world	
<b>ER0815</b>	Other financial liabilities (debt securities issued)	
<b>R0820</b>	Insurance & intermediaries payables	10,713
<b>R0830</b>	Reinsurance payables	0
<b>R0840</b>	Payables (trade, not insurance)	1,845
<b>R0850</b>	Subordinated liabilities	0
<b>R0860</b>	Subordinated liabilities not in BOF	0
<b>R0870</b>	Subordinated liabilities in BOF	0
<b>R0880</b>	Any other liabilities, not elsewhere shown	0
<b>R0900</b>		
	<b>Total liabilities</b>	<b>6,716,344</b>
<b>R1000</b>	<b>Excess of assets over liabilities</b>	<b>40,758</b>

## F. Appendix

### S.05.01.02

#### Premiums, claims and expenses by Line of Business

Life	Line of Business for: life insurance obligations						Life reinsurance obligations		Total
	Health insurance C0210	Insurance with profit participation C0220	Index-linked and unit-linked insurance C0230	Other life insurance C0240	Annuities stemming from non-life insurance contracts and relating to health insurance obligations C0250	Annuities stemming from non-life insurance contracts and relating to insurance obligations other than health insurance obligations C0260	Health reinsurance C0270	Life reinsurance C0280	Total C0300
	<b>Premiums written</b>								
<b>R1410</b>	<i>Gross</i>		468,409						468,409
<b>R1420</b>	<i>Reinsurers' share</i>							0	
<b>R1500</b>	<i>Net</i>		468,409						468,409
	<b>Premiums earned</b>								
<b>R1510</b>	<i>Gross</i>		468,409						468,409
<b>R1520</b>	<i>Reinsurers' share</i>							0	
<b>R1600</b>	<i>Net</i>		468,409						468,409
	<b>Claims incurred</b>								
<b>R1610</b>	<i>Gross</i>		231,289						231,289
<b>R1620</b>	<i>Reinsurers' share</i>							0	
<b>R1700</b>	<i>Net</i>		231,289						231,289
	<b>Changes in other technical provisions</b>								
<b>R1710</b>	<i>Gross</i>		365,879						365,879
<b>R1720</b>	<i>Reinsurers' share</i>							0	
<b>R1800</b>	<i>Net</i>		365,879						365,879
<b>R1900</b>	<b>Expenses incurred</b>		<b>13,469</b>						<b>13,469</b>
<b>R2500</b>	<b>Other expenses</b>								
<b>R2600</b>	<b>Total expenses</b>		<b>13,469</b>						<b>13,469</b>

## F. Appendix

### S.05.02.02

#### Premiums, claims and expenses by country

		C0150	C0160	C0170	C0180	C0190	C0200	C0210
Life	Home Country	Top 5 countries (by amount of gross premiums written) - life obligations						Total Top 5 and home country
<b>R1400</b>		GB	IT					
		C0220	C0230	C0240	C0250	C0260	C0270	C0280
Premiums written								
<b>R1410</b>	Gross	0	468,409	0				468,409
<b>R1420</b>	Reinsurers' share	0						0
<b>R1500</b>	Net	0	468,409	0	0	0	0	468,409
Premiums earned								
<b>R1510</b>	Gross	0	468,409	0				468,409
<b>R1520</b>	Reinsurers' share	0						0
<b>R1600</b>	Net	0	468,409	0	0	0	0	468,409
Claims incurred								
<b>R1610</b>	Gross	0	221,545	9,744				231,289
<b>R1620</b>	Reinsurers' share	0						0
<b>R1700</b>	Net	0	221,545	9,744				231,289
Changes in other technical provisions								
<b>R1710</b>	Gross	0	365,195	684				365,879
<b>R1720</b>	Reinsurers' share	0						0
<b>R1800</b>	Net	0	365,195	684	0	0	0	365,879
<b>R1900</b>	Expenses incurred	<b>4,006</b>	8,932	531	0	0	0	<b>13,469</b>
<b>R2500</b>	Other expenses							
<b>R2600</b>	Total expenses							<b>13,469</b>

## F. Appendix

### S.12.01.02

Life and Health SLT Technical Provisions		Index-linked and unit-linked insurance			Other life insurance			Annuities stemming from non-life insurance contracts and relating to insurance obligation other than health insurance obligations	Accepted reinsurance	Total (Life other than health insurance, including Unit-Linked)
	Insurance with profit participation		Contracts without options and guarantees	Contracts with options or guarantees		Contracts without options and guarantees	Contracts with options or guarantees			
	C0020	C0030	C0040	C0050	C0060	C0070	C0080	C0090	C0100	C0150
<b>R0010</b>	<b>Technical provisions calculated as a whole</b>	<b>6,715,505</b>								<b>6,715,505</b>
<b>R0020</b>	Total Recoverables from reinsurance/SPV and Finite Re after the adjustment for expected losses due to counterparty default associated to TP calculated as a whole									<b>0</b>
	<b>Technical provisions calculated as a sum of BE and RM</b>									
	Best estimate									
<b>R0030</b>	<b>Gross Best Estimate</b>		<b>-28,705</b>							<b>-28,705</b>
<b>R0080</b>	Total Recoverables from reinsurance/SPV and Finite Re after the adjustment for expected losses due to counterparty default									<b>0</b>
<b>R0090</b>	Best estimate minus recoverables from reinsurance/SPV and Finite Re		<b>-28,705</b>	<b>0</b>						<b>-28,705</b>
<b>R0100</b>	<b>Risk margin</b>	<b>16,986</b>								<b>16,986</b>
	<b>Amount of the transitional on Technical Provisions</b>									
<b>R0110</b>	Technical Provisions calculated as a whole									<b>0</b>
<b>R0120</b>	Best estimate									<b>0</b>
<b>R0130</b>	Risk margin									<b>0</b>
<b>R0200</b>	<b>Technical provisions - total</b>	<b>6,703,786</b>								<b>6,703,786</b>

## F. Appendix

### S.23.01.01

#### Own Funds

	Basic own funds before deduction for participations in other financial sector as foreseen in article 68 of Delegated Regulation 2015/35	Total	Tier 1 unrestricted	Tier 1 restricted	Tier 2	Tier 3
		C0010	C0020	C0030	C0040	C0050
R0010	Ordinary share capital (gross of own shares)	1,369	1,369		0	
R0030	Share premium account related to ordinary share capital	5,531	5,531		0	
R0040	Initial funds, members' contributions or the equivalent basic own-fund item for mutual and mutual-type undertakings	0	0		0	
R0050	Subordinated mutual member accounts	0		0	0	0
R0070	Surplus funds	0	0			
R0090	Preference shares	0		0	0	0
R0110	Share premium account related to preference shares	0		0	0	0
R0130	Reconciliation reserve	-17,942	-17,942			
R0140	Subordinated liabilities	0		0	0	0
R0160	An amount equal to the value of net deferred tax assets	0				0
R0180	Other own fund items approved by the supervisory authority as basic own funds not specified above	51,800	51,800	0	0	0
	<b>Own funds from the financial statements that should not be represented by the reconciliation reserve and do not meet the criteria to be classified as Solvency II own funds</b>					
R0220	Own funds from the financial statements that should not be represented by the reconciliation reserve and do not meet the criteria to be classified as Solvency II own funds	0				



## F. Appendix

### S.23.01.01

Own Funds					
	Total	Tier 1 unrestricted	Tier 1 restricted	Tier 2	Tier 3
	C0010	C0020	C0030	C0040	C0050
<b>Deductions</b>					
<b>R0230</b> Deductions for participations in financial and credit institutions	0				
<b>R0290 Total basic own funds after deductions</b>	40,758	40,758	0	0	0
<b>Ancillary own funds</b>					
<b>R0300</b> Unpaid and uncalled ordinary share capital callable on demand	0				
<b>R0310</b> Unpaid and uncalled initial funds, members' contributions or the equivalent basic own fund item for mutual and mutual - type undertakings, callable on demand	0				
<b>R0320</b> Unpaid and uncalled preference shares callable on demand	0				
<b>R0330</b> A legally binding commitment to subscribe and pay for subordinated liabilities on demand	0				
<b>R0340</b> Letters of credit and guarantees under Article 96(2) of the Directive 2009/138/EC	0				
<b>R0350</b> Letters of credit and guarantees other than under Article 96(2) of the Directive 2009/138/EC	0				
<b>R0360</b> Supplementary members calls under first subparagraph of Article 96(3) of the Directive 2009/138/EC	0				
<b>R0370</b> Supplementary members calls - other than under first subparagraph of Article 96(3) of the Directive 009/138/EC	0				
<b>R0390</b> Other ancillary own funds	0				
<b>R0400 Total ancillary own funds</b>	0			0	0

## F. Appendix

### S.23.01.01

#### Own Funds

	Total	Tier 1 unrestricted	Tier 1 restricted	Tier 2	Tier 3
	C0010	C0020	C0030	C0040	C0050
<b>Available and eligible own funds</b>					
<b>R0500</b> Total available own funds to meet the SCR	40,758	40,758	0	0	0
<b>R0510</b> Total available own funds to meet the MCR	40,758	40,758	0	0	
<b>R0540</b> Total eligible own funds to meet the SCR	40,758	40,758	0	0	0
<b>R0550</b> Total eligible own funds to meet the MCR	40,758	40,758	0	0	
<b>R0580 SCR</b>			27,031		
<b>R0600 MCR</b>			12,164		
<b>R0620 Ratio of Eligible own funds to SCR</b>		150.78%			
<b>R0640 Ratio of Eligible own funds to MCR</b>		335.08%			
<b>Reconciliation reserve</b>	C0060				
<b>R0700</b> Excess of assets over liabilities	40,758				
<b>R0710</b> Own shares (held directly and indirectly)	0				
<b>R0720</b> Foreseeable dividends, distributions and charges					
<b>R0730</b> Other basic own fund items	58,700				
<b>R0740</b> Adjustment for restricted own fund items in respect of matching adjustment portfolios and ring fenced funds	0				
<b>R0760 Reconciliation reserve</b>	-17,942				
<b>Expected profits</b>					
<b>R0770</b> Expected profits included in future premiums (EPIFP) - Life business					
<b>R0780</b> Expected profits included in future premiums (EPIFP) - Non- life business					
<b>R0790 Total Expected profits included in future premiums (EPIFP)</b>	0				

## F. Appendix

### S.25.01.21

#### Solvency Capital Requirement - for undertakings on Standard Formula

	Gross solvency capital requirement C0110	USP C0080	Simplifications C0090
<b>R0010</b> Market risk	11,953		
<b>R0020</b> Counterparty default risk	662		
<b>R0030</b> Life underwriting risk	19,461		
<b>R0040</b> Health underwriting risk	0		
<b>R0050</b> Non-life underwriting risk	0		
<b>R0060</b> Diversification	6,606		
<b>R0070</b> Intangible asset risk	0		
<b>R0100 Basic Solvency Capital Requirement</b>	<b>25,470</b>		
<b>Calculation of Solvency Capital Requirement</b>	<b>C0100</b>		
<b>R0130</b> Operational risk	1,560		
<b>R0140</b> Loss-absorbing capacity of technical provisions	0		
<b>R0150</b> Loss-absorbing capacity of deferred taxes	0		
<b>R0160</b> Capital requirement for business operated in accordance with Art. 4 of Directive 2003/41/EC	0		
<b>R0200 Solvency Capital Requirement excluding capital add-on</b>	<b>27,031</b>		
<b>R0210</b> Capital add-ons already set	0		
<b>R0220 Solvency capital requirement</b>	<b>27,031</b>		
<b>Other information on SCR</b>			
<b>R0400</b> Capital requirement for duration-based equity risk sub-module	0		
<b>R0410</b> Total amount of Notional Solvency Capital Requirements for remaining part	0		
<b>R0420</b> Total amount of Notional Solvency Capital Requirements for ring fenced funds	0		
<b>R0430</b> Total amount of Notional Solvency Capital Requirements for matching adjustment portfolios	0		
<b>R0440</b> Diversification effects due to RFF nSCR aggregation for article 304	0		

## F. Appendix

### S.28.01.01

#### Minimum Capital Requirement - Only life or only non-life insurance or reinsurance activity

Linear formula component for non-life insurance and reinsurance obligations		C0010		
R0010 MCR <sub>NL</sub> Result		0		
			Net (of reinsurance/ SPV) best estimate and TP calculated as a whole	Net (of reinsurance) written premiums in the last 12 months
			C0020	C0030
R0020 Medical expense insurance and proportional reinsurance				
R0030 Income protection insurance and proportional reinsurance				
R0040 Workers' compensation insurance and proportional reinsurance				
R0050 Motor vehicle liability insurance and proportional reinsurance				
R0060 Other motor insurance and proportional reinsurance				
R0070 Marine, aviation and transport insurance and proportional reinsurance				
R0080 Fire and other damage to property insurance and proportional reinsurance				
R0090 General liability insurance and proportional reinsurance				
R0100 Credit and suretyship insurance and proportional reinsurance				
R0110 Legal expenses insurance and proportional reinsurance				
R0120 Assistance and proportional reinsurance				
R0130 Miscellaneous financial loss insurance and proportional reinsurance				
R0140 Non-proportional health reinsurance				
R0150 Non-proportional casualty reinsurance				
R0160 Non-proportional marine, aviation and transport reinsurance				
R0170 Non-proportional property reinsurance				

## F. Appendix

### S.28.01.01

#### Minimum Capital Requirement - Only life or only non-life insurance or reinsurance activity

<b>Linear formula component for life insurance and reinsurance obligations</b>	<b>C0040</b>		
<b>R0200 MCR<sub>L</sub> Result</b>	<b>46,810</b>		
		<b>Net (of reinsurance/SPV) best estimate and TP calculated as a whole</b>	<b>Net (of reinsurance/SPV) total capital at risk</b>
	<b>C0050</b>	<b>C0060</b>	
<b>R0210</b> Obligations with profit participation - guaranteed benefits			
<b>R0220</b> Obligations with profit participation - future discretionary benefits			
<b>R0230</b> Index-linked and unit-linked insurance obligations		6,686,800	
<b>R0240</b> Other life (re)insurance and health (re)insurance obligations			
<b>R0250</b> Total capital at risk for all life (re)insurance obligations			3,955
<b>Overall MCR calculation</b>	<b>C0070</b>		
<b>R0300</b> Linear MCR	46,810		
<b>R0310</b> SCR	27,031		
<b>R0320</b> MCR cap	12,164		
<b>R0330</b> MCR floor	6,758		
<b>R0340</b> Combined MCR	12,164		
<b>R0350</b> Absolute floor of the MCR	3,296		
<b>R0400 Minimum Capital Requirement</b>	<b>12,164</b>		



Canada Life International Assurance (Ireland) DAC, registered in Ireland no. 440141. Registered office: Irish Life Centre, Lower Abbey Street, Dublin 1, Ireland.  
Telephone: +44 (0) 1624 820200 Fax: +44 (0) 1624 820201 [www.canadalifeinternational.ie](http://www.canadalifeinternational.ie) Member of the Association of International Life Offices.

Canada Life International Assurance (Ireland) DAC is authorised and regulated by the Central Bank of Ireland. Category A Insurance Permit holder with the Jersey Financial Services Commission.